Before any new products we may offer are introduced into the U.S. market, we must obtain prior authorization from the FDA. This authorization is based on a review by the FDA of the medical device’s safety and effectiveness for its intended uses. The process of obtaining clearances or approvals from the FDA and other applicable regulatory authorities can be expensive, uncertain and time consuming.
In addition, we may not be able to obtain necessary approvals for clinical testing or for the manufacturing or marketing of any of our products in the United States or in other countries. If regulatory approvals for any of our other products are not obtained on a timely basis, or not approved as submitted, or at all, it could have a significant negative effect on our financial condition and results of operations. Additionally, delays in receipt of regulatory approvals for our products or failure to receive such approvals, the loss of previously obtained approvals, or failure to comply with existing or future regulatory requirements would have a significant negative effect on our financial condition and results of operations.
Even if such an approval is obtained, our failure to comply with applicable regulatory approvals could, among other things, result in fines, suspension of regulatory approvals, product recalls, operating restrictions and criminal prosecution. In addition, government regulations may be established that could prevent, delay, modify or rescind regulatory approval of our products. Any such position or change of position by the FDA may adversely impact our business and financial condition. Regulatory approvals, if granted, may include significant limitations on the indicated uses for which our products may be marketed in the United States or in other countries. In addition to obtaining such approvals, the FDA and foreign regulatory authorities may impose numerous other requirements on us. The FDA prohibits the marketing of approved medical devices for unapproved uses. In addition, product approvals can be withdrawn for failure to comply with regulatory standards or the occurrence of unforeseen problems following initial marketing.
In addition, the health care industry in the United States is generally subject to fundamental change due to regulatory as well as political influences. We anticipate that Congress and state legislatures will continue to review and assess alternative health care delivery and payment systems. Potential approaches that have been considered include controls on health care spending through limitations on the growth of private purchasing groups and price controls. We cannot predict what impact the adoption of any federal or state health care reform measures may have on our business.
The Patient Protection and Affordable Care Act and Health Care and Education Reconciliation Act of 2010 were enacted into law in March 2010. As a U.S. based company with significant sales in the United States, these health care reform laws will materially impact us and are expected to materially impact us. Certain provisions of these laws will not be effective for a number of years and there are many programs and requirements for which the details have not yet been fully established. Accordingly, it is unclear what the full impact will be from the recent health care reform legislation. However, beginning in January 2013, the legislation imposed a 2.3% excise tax on sales of our Cooled ThermoTherapy and Prostiva products in the United States. We expect the new tax will materially and adversely affect our business, cash flows and results of operations. For the fiscal years ended June 30, 2014 and 2013, we paid approximately $223,000 and $106,000, respectively in medical device excise tax.
The laws also focus on a number of Medicare provisions aimed at improving quality and decreasing costs. The Medicare provisions include value-based payment programs, increased funding of comparative effectiveness research, reduced hospital payments for avoidable readmissions and hospital acquired conditions, and pilot programs to evaluate alternative payment methodologies that promote care coordination (such as bundled physician and hospital payments). Additionally, the recent health care reform legislation includes a reduction in the annual rate of inflation for Medicare payments to hospitals that began in 2011 and the establishment of an independent payment advisory board to recommend ways of reducing the rate of growth in Medicare spending beginning in 2014. We cannot predict what healthcare programs and regulations will be ultimately implemented at the federal or state level, or the effect of any future legislation or regulation. However, any changes that lower reimbursement for our products or reduce medical procedure volumes could adversely affect our business and results of operations.
Table of Contents
We are dependent upon a limited number of third-party suppliers for our products.
We manufacture CoolWave control units and single-use treatment catheters for use with CoolWave control units at our suburban Minneapolis facility. Our success will depend upon our ability to cost-effectively manufacture a reliable product and deliver that product in a timely manner. We may encounter difficulties in maintaining production efficiencies, quality control and assurance, component supply and qualified personnel. We cannot offer assurance that we will be able to manufacture a reliable product and deliver that product to customers in a timely fashion. Our failure to maintain a reputation among our customers as a timely, responsive manufacturer, or our failure to remedy manufacturing issues in a timely manner and to our customers’ satisfaction, or higher than expected manufacturing costs, would adversely affect our business.
Other than the CoolWave control units and CTC Advance® catheter procedure kits, we outsource the remaining manufacturing for our products. We assemble CoolWave control units and procedure kits using materials and components supplied by various subcontractors and suppliers, as well as components we fabricate. We rely on single sources for several components, one of which is obtained from a source that has a patent for the technology.
We also outsource the manufacturing of the Prostiva product line. Our reliance on outside suppliers for our components and for the Prostiva product involves risks, including limited control over the price and uncertainty regarding timely delivery and quality of parts and product. The start-up, transfer, termination or interruption of any of these relationships or products, or the failure of these manufacturers or suppliers, some of which operate in countries outside of the United States, to supply products or components to us on a timely basis or in sufficient quantities, likely would cause us to be unable to meet customer orders for our products and harm our reputation with customers and our business. Identifying and qualifying alternative suppliers of components or manufacturers of products takes time and involves significant additional costs and may delay the production of our products.
If we obtain a new supplier for a component, manufacture our product with an alternative component, or if our products are manufactured by an alternative manufacturer, we likely will need either FDA approval of a pre-market approval (PMA) supplement or FDA clearance of a 510(k) application to make a change in component or product manufacturing. The process for obtaining FDA approval or FDA clearance may result in extended delays in delivery of our product to customers and increased costs associated with the change.
The failure of our third-party manufacturers to manufacture the products for us, and the failure of our components suppliers to supply us with the components, consistent with our requirements as to quality, quantity and timeliness, would materially harm our business.
Our business of the manufacturing, marketing, and sale of medical devices involves the risk of liability claims and such claims could seriously harm our business, particularly if our insurance coverage is inadequate.
Our business exposes us to potential product liability claims that are inherent in the testing, production, marketing and sale of medical devices. Like other participants in the medical device industry, we are from time to time involved in lawsuits, claims and proceedings alleging product liability and related claims such as negligence. If any current or future product liability claims become substantial, our reputation could be damaged significantly, thereby harming our business. We may be required to pay substantial damage awards as a result of any successful product liability claims. Any product liability claim against us, whether with or without merit, could result in costly litigation, and divert the time, attention, and resources of our management.
As a result of our exposure to product liability claims, we currently carry product liability insurance covering our products with policy limits per occurrence and in the aggregate that we have deemed to be sufficient. Our insurance may not cover certain product liability claims or our liability for any claims may exceed our coverage limits. Therefore, we cannot predict whether this insurance is sufficient, or if not, whether we will be able to obtain sufficient insurance to cover the risks associated with our business or whether such insurance will be available at premiums that are commercially reasonable. In addition, these insurance policies must be renewed annually. Although we have been able to obtain liability insurance, such insurance may not be available in the future on acceptable terms, if at all. A successful claim against us or settlement by us with respect to uninsured liabilities or in excess of our insurance coverage, or our inability to maintain insurance in the future, or any claim that results in significant costs to or adverse publicity against us, could have a material adverse effect on our business, financial condition and results of operations.
25
Table of Contents
We are dependent on adequate protection of our patent and proprietary rights.
We rely on patents, trade secrets, trademarks, copyrights, know-how, license agreements and contractual provisions to establish and protect our intellectual property rights. However, these legal means afford us only limited protection and may not adequately protect our rights or remedies to gain or keep any advantages we may have over our competitors.
Other competitors may independently develop the same or similar technologies or otherwise obtain access to our technology and trade secrets. Our competitors, many of which have substantial resources and may make substantial investments in competing technologies, may apply for and obtain patents that will prevent, limit, or interfere with our ability to manufacture or market our products. Further, while we do not believe that any of our products or processes interfere with the rights of others, third parties may nonetheless assert patent infringement claims against us in the future.
Costly litigation may be necessary to enforce patents issued or licensed to us, to protect trade secrets or “know-how” we own, to defend us against claimed infringement of the rights of others or to determine the ownership, scope, or validity of our proprietary rights and the rights of others. In connection with the settlement of a patent infringement suit we filed in March 2002, we granted, in January 2004, ProstaLund AB, ProstaLund Operations AB and Circon Corporation (a/k/a ACMI Corporation) a non-exclusive, royalty free license under certain of our patents to sell the ProstaLund transurethral microwave thermotherapy system marketed in the United States by ACMI Corporation as the CoreTherm device.
Any claim of infringement against us may involve significant liabilities to third parties, could require us to seek licenses from third parties, and could prevent us from manufacturing, selling, or using our products. The occurrence of this litigation or the effect of an adverse determination in any of this type of litigation could have a material adverse effect on our business, financial condition and results of operations.
Our products may be subject to product recalls even after receiving FDA clearance or approval, which would harm our reputation and our business.
The FDA and similar governmental authorities in other countries in which our products are sold, have the authority to request and, in some cases, require the recall of our products in the event of material deficiencies or defects in design, manufacture or labeling. A government-mandated or voluntary recall by us could occur as a result of component failures, manufacturing errors, labeling errors or design defects. Any recall of product would divert managerial and financial resources, harm our reputation with our customers and damage our business.
We are dependent on key personnel.
Our failure to attract and retain skilled personnel could hinder the management of our business, our research and development, our sales and marketing efforts, and our manufacturing capabilities. Our future success depends to a significant degree upon the continued services of key senior management personnel, including Gregory J. Fluet, our Chief Executive Officer and Interim Chief Financial Officer and Lisa Ackermann, our Executive Vice President, Sales and Marketing. Each of these members of senior management is employed “at will” by us. However, if there is a change in control and we terminate Mr. Fluet’s or Ms. Ackermann’s employment without cause, we would be required to make specified payments to him or her as described in an amended and restated change of control letter agreement dated April 23, 2012. We do not have key person life insurance on any member of senior management.
Our future success also depends on our continuing ability to attract, retain and motivate highly qualified managerial, technical and sales personnel. Our inability to retain or attract qualified personnel could have a significant negative effect and thereby materially harm our business and financial condition.
26
Table of Contents
Risks Related to the Prostiva RF Therapy System and Related Agreements
On September 6, 2011, we entered into a license agreement and other agreements with Medtronic, Inc. (“Medtronic”) and its subsidiary, VidaMed, Inc., relating to the Prostiva RF Therapy System. In addition, on June 28, 2013 we entered into a Restructuring Agreement and Amendment to Transaction Documents (the “Restructuring Agreement”). For a summary of the agreements with Medtronic, please see “Prostiva Related Agreements” in the “Business” section of this Annual Report on Form 10-K. The addition of the Prostiva RF product to our business and these agreements present additional risks to us and our business that are described below.
If we fail to comply with our obligations under our license agreement with Medtronic or if the license agreement terminates for any reason, we would lose the ability to sell the Prostiva product.
In September 2011, we entered into a License Agreement with Medtronic, Inc. and its subsidiary, VidaMed, Inc., that granted us an exclusive worldwide license to the Prostiva RF Therapy System in the field of the radio frequency treatment of the prostate, including BPH. At the same time we entered into the License Agreement, we also entered into other agreements with Medtronic and VidaMed, including a Transition Services and Supply Agreement, an Acquisition Option Agreement and an Asset Purchase Agreement. Summaries of each of these agreements may be found in the “Business” section of this Annual Report on Form 10-K under the heading “Prostiva Related Agreements.”
The term of the License Agreement is ten years or the earlier closing date of a purchase under the Acquisition Option Agreement. In addition, either party may terminate the License Agreement by written notice for breach after an opportunity to cure, and Medtronic may terminate the License Agreement in the event of our bankruptcy or insolvency. The License Agreement also will automatically terminate concurrently with certain terminations of the Transition Services and Supply Agreement, including terminations relating to regulatory challenges specified under the Transition Services and Supply Agreement. Upon termination of the License Agreement, all rights to the Prostiva intellectual property will revert back to Medtronic and the Transition Services and Supply Agreement and Acquisition Option Agreement will terminate. Further, upon termination of the License Agreement by Medtronic as a result of our breach or bankruptcy or default on the promissory note entered into with Medtronic on June 28, 2013, Medtronic will have the right, but not the obligation, to repurchase the assets from us that we previously purchased under the Asset Purchase Agreement for the same purchase price we previously paid.
Any termination of the License Agreement would result in the loss of the right to sell the Prostiva product and would materially harm our business. In addition, if the License Agreement were terminated, we would not be able to recoup the transaction expenses associated with the acquisition of the Prostiva business or the expenses we have incurred associated with the integration of the Prostiva business.
We have not paid certain amounts due to Medtronic under the license agreement, which with proper notice and opportunities to cure would entitle Medtronic to terminate the license agreement for breach and entitle Medtronic to accelerate and demand repayment of our $5.3 million promissory note to Medtronic.
Under the license agreement, royalty payments for Prostiva products are paid one year in arrears based on the contract year. The royalty payment due in the second quarter of fiscal year 2014 of $650,000 has not been paid. This amount is included in the short-term deferred acquisition payment liability as of June 30, 2014. In addition, we did not pay the annual $65,000 licensing maintenance fee due on October 6, 2013 which is included in other accrued expenses as of June 30, 2014.
The non-payment does not entitle Medtronic to terminate the license agreement unless Medtronic provides written notice and an opportunity to cure the default. The non-payment under the license agreement is also not an event of default under our promissory note to Medtronic dated June 28, 2013 in the principal amount of approximately $5.3 million (the “Note”) unless Medtronic provides written notice and an opportunity to cure the default. We have not received any notice from Medtronic as of the date of this filing.
27
Table of Contents
Medtronic may terminate the license agreement by written notice for breach after an opportunity to cure and in the event of our bankruptcy or insolvency. If the license agreement is terminated, our rights to sell the Prostiva product would be terminated. Further, upon an event of default under the Note (which includes a material breach of the license agreement or other transaction documents after written notice and an opportunity to cure), Medtronic may accelerate and declare due all amounts outstanding under the Note. If Medtronic accelerated and declared due all amounts outstanding under the Note, we would not have adequate cash to repay the amounts due, resulting in a loss of control of our business or bankruptcy.
The Company’s ability to continue as a going concern is also dependent upon avoiding an event of default under the Note and avoiding termination of the license relating to the Prostiva product, whether by negotiation with Medtronic, cure of any non-payment giving rise to an event of default or termination, or otherwise. There can be no assurance that we will be able to cure any potential event of default of the Note or cure any breach of any agreement with Medtronic, maintain compliance with our agreements with Medtronic, raise additional capital or otherwise improve our liquidity, or improve our operating or financial performance. The Company’s cash needs and availability will be determined by a number of factors including operating performance and the timing of payment of the $650,000 in annual royalties.
The Prostiva RF Therapy System license, Restructuring Agreement and other agreements require significant future payments.
Under the License Agreement, Transition Services and Supply Agreement, and Restructuring Agreement with Medtronic for the Prostiva RF Therapy System, we are obligated to make certain future payments, including:
| | |
| • | $65,000 annually as a license maintenance fee; |
| • | Royalties on net sales of product payable thirty days following the end of each contract year (or minimum royalty amounts beginning in the second contract year that are payable ninety days following the end of each contract year); |
| • | five equal annual payments of principal and accrued interest beginning on March 31, 2015 on the $5,332,538 promissory note which accrues interest at 6 percent compounded annually. The promissory note represents amounts owed to Medtronic for inventory received as part of the acquisition of the Prostiva business, as well as inventory purchased subsequent to the acquisition. |
Our failure to pay these amounts when due with proper notice and opportunities to cure, would be a breach of the agreement, entitling Medtronic to terminate these agreements and our right to sell the Prostiva product after proper notice and an opportunity to cure.
The addition of the Prostiva RF Therapy System to our product portfolio may result in the exacerbation of certain risks to our business.
As detailed above, we face a number of risks in our business and risks associated with our Cooled ThermoTherapy products. Because the addition of the Prostiva RF Therapy System to our product portfolio presents some of these same risks to us, these risks may be magnified. For example, with the Prostiva RF Therapy System, we face risks associated with:
| | |
| • | reliance on third party reimbursement; |
| • | intense competition, primarily from pharmaceutical companies that market and sell BPH medication; |
| • | our lack of diversification because our products are minimally invasive treatments for BPH; |
| • | significant impact of government regulation; |
| • | risk of product liability claims; |
| • | risk of managing third party manufacturers; and |
| • | the possibility of product recalls. |
If we are unable to address these risks as they relate to both the CTT and Prostiva products, our results of operations, cash flows and the value of our common stock would be negatively impacted.
28
Table of Contents
| |
ITEM 1B. | UNRESOLVED STAFF COMMENTS |
Not applicable.
We lease approximately 26,000 square feet of office, manufacturing and warehouse space in a suburb of Minneapolis, Minnesota. On September 9, 2010, the Company entered into a new lease agreement with our current landlord, covering the same square footage, for a period of seventy-two months, effective August 1, 2010. We believe our facilities will be sufficient to meet our current and future requirements and that additional space at or near the current location will be available at a reasonable cost if additional space is required in the future.
We have been and are involved in various legal proceedings and other matters that arise in the normal course of our business, including product liability claims that are inherent in the testing, production, marketing and sale of medical devices. Based upon currently available information, we believe that the ultimate resolution of these matters will not have a material effect on the financial position, liquidity or results of operations of the Company.
| |
ITEM 4. | MINE SAFETY DISCLOSURES |
Not applicable.
29
Table of Contents
PART II
| |
ITEM 5. | MARKET FOR THE REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES |
Our common stock was traded on The Nasdaq Capital Market under the symbol “ULGX” through June 6, 2013. As a result of our voluntary delisting from the Nasdaq Capital Market on June 5, 2013, our common stock began trading on the OTCQB Marketplace (“OTCQB”) under the symbol “ULGX” on June 7, 2013. The following table sets forth quarterly high and low last-sale prices of our common stock for each quarter during the past two fiscal years.
| | | | | | | | | | | | | | | | |
| | | | | Quarter | |
Fiscal Year | | | | | First | | Second | | Third | | Fourth | |
| | | | | | | | | | | | | | | | |
2014 | | | High | | $ | 0.40 | | $ | 0.33 | | $ | 0.20 | | $ | 0.20 | |
| | | Low | | | 0.15 | | | 0.14 | | | 0.14 | | | 0.14 | |
| | | | | | | | | | | | | | | | |
2013 | | | High | | $ | 1.00 | | $ | 0.84 | | $ | 0.77 | | $ | 0.54 | |
| | | Low | | | 0.64 | | | 0.61 | | | 0.54 | | | 0.16 | |
The foregoing prices reflect inter-dealer prices, without dealer markup, markdown or commissions, and may not represent actual transactions.
Dividends
To date, we have not declared or paid any cash dividends on our common stock, and we do not intend to do so in the foreseeable future.
Equity Compensation Plan Information
The table below presents our equity compensation plan information as of June 30, 2014:
| | | | | | | | | | | | | |
Plan Category | | | Number of securities to be
issued upon exercise of
outstanding options,
warrants and rights | | | Weighted-average exercise
price of outstanding options,
warrants and rights | | | Number of securities
remaining available for
future issuance under equity
compensation plans
(excluding securities
reflected in first column) | |
Equity compensation plans approved by security holders | | | | 2,050,344 | | | | $ 1.17 | | | | 1,319,354 | |
Equity compensation plan not approved by security holders | | | | - | | | | - | | | | - | |
Total | | | | 2,050,344 | | | | $ 1.17 | | | | 1,319,354 | |
The “equity compensation plans approved by security holders” listed above represent shares issuable under the Urologix, Inc. 2012 Stock Incentive Plan, an “employee benefit plan” as defined by Rule 405 of Regulation C of the Securities Act of 1933. Shareholders approved the most recent Stock Incentive Plan at the 2012 Annual Meeting of Shareholders held on November 16, 2012.
30
Table of Contents
| |
ITEM 6. | SELECTED FINANCIAL DATA |
| | | | | | | | | | | | | | | | |
| | Years ended June 30, | |
| | 2014 | | 2013 | | 2012 | | 2011 | | 2010 | |
| | (in thousands, except per share data) | |
Statements of Operations Data: | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
Sales | | $ | 14,235 | | $ | 16,590 | | $ | 17,027 | | $ | 12,571 | | $ | 14,771 | |
Cost of goods sold | | | 8,142 | (1) | | 8,407 | (2) | | 8,645 | | | 6,030 | | | 6,569 | |
| | | | | | | | | | | | | | | | |
Gross profit | | | 6,093 | | | 8,183 | | | 8,382 | | | 6,541 | | | 8,202 | |
| | | | | | | | | | | | | | | | |
Costs and Expenses: | | | | | | | | | | | | | | | | |
Sales and marketing | | | 5,850 | | | 7,719 | | | 7,027 | | | 5,197 | | | 5,657 | |
General and administrative | | | 2,299 | | | 2,515 | | | 3,393 | | | 2,808 | | | 2,944 | |
Research and development | | | 1,625 | | | 2,269 | | | 2,189 | | | 2,238 | | | 1,834 | |
Change in value of acquisition consideration | | | (105 | ) | | (447 | ) | | (172 | ) | | - | | | - | |
Impairment of goodwill | | | 3,036 | | | - | | | - | | | - | | | - | |
Gain on demutualization | | | - | | | (321 | ) | | - | | | - | | | - | |
Medical device tax | | | 223 | | | 106 | | | - | | | - | | | - | |
Amortization of identifiable intangible assets | | | 95 | | | 104 | | | 90 | | | 24 | | | 24 | |
Impairment of identifiable intangible assets | | | - | | | 160 | (3) | | - | | | - | | | - | |
| | | | | | | | | | | | | | | | |
Total costs and expenses | | | 13,023 | | | 12,105 | | | 12,527 | | | 10,267 | | | 10,459 | |
| | | | | | | | | | | | | | | | |
Operating loss | | | (6,930 | ) | | (3,922 | ) | | (4,145 | ) | | (3,726 | ) | | (2,257 | ) |
Interest income/(expense), net | | | (693 | ) | | (555 | ) | | (482 | ) | | 1 | | | - | |
Gain on debt extinguishment | | | - | | | 206 | | | - | | | - | | | - | |
Foreign currency exchange gain/(loss) | | | (1 | ) | | (7 | ) | | (13 | ) | | - | | | - | |
Loss before income taxes | | | (7,624 | ) | | (4,278 | ) | | (4,640 | ) | | (3,725 | ) | | (2,257 | ) |
Income tax expense (benefit) | | | (16 | ) | | 14 | | | 55 | | | 8 | | | (88 | ) |
Net loss | | $ | (7,608 | ) | $ | (4,292 | ) | $ | (4,695 | ) | $ | (3,733 | ) | $ | (2,169 | ) |
| | | | | | | | | | | | | | | | |
Basic: | | | | | | | | | | | | | | | | |
Net loss per common share: | | $ | (0.36 | ) | $ | (0.21 | ) | $ | (0.32 | ) | $ | (0.26 | ) | $ | (0.15 | ) |
Weighted average shares used in computing net loss per share | | | 21,219 | | | 20,703 | | | 14,741 | | | 14,556 | | | 14,508 | |
Diluted: | | | | | | | | | | | | | | | | |
Net loss per common share: | | $ | (0.36 | ) | $ | (0.21 | ) | $ | (0.32 | ) | $ | (0.26 | ) | $ | (0.15 | ) |
Weighted average shares used in computing net loss per share | | | 21,219 | | | 20,703 | | | 14,741 | | | 14,556 | | | 14,508 | |
| | | | | | | | | | | | | | | | |
| | 2014 | | 2013 | | 2012 | | 2011 | | 2010 | |
Balance Sheet Data: | | | | | | | | | | | | | | | | |
Cash and cash equivalents | | $ | 718 | | $ | 2,290 | | $ | 1,899 | | $ | 3,061 | | $ | 5,702 | |
Working capital/(deficit)(4) | | | (612 | ) | | 3,484 | | | (1,520 | ) | | 4,038 | | | 6,720 | |
Total assets | | | 5,667 | | | 12,527 | | | 12,676 | | | 6,763 | | | 10,203 | |
Total liabilities | | | 12,644 | | | 12,107 | | | 12,050 | | | 1,917 | | | 1,997 | |
Shareholders’ equity/(deficit) | | | (6,977 | ) | | 420 | | | 626 | | | 4,846 | | | 8,206 | |
| |
(1) | Includes a $739,000 non-cash charge to write down the value of Prostiva capital equipment inventory. |
|
(2) | Includes a $274,000 non-cash charge to partially impair our developed technology acquired as part of the Prostiva acquisition as of June 30, 2013. |
31
Table of Contents
| |
(3) | Represents the following non-cash charges to partially impair intangible assets acquired as part of the Prostiva acquisition as of June 30, 2013: |
| | |
| Customer Base | $95,000 |
| Trademarks | $65,000 |
| |
(4) | Significant increase in working capital from fiscal year 2012 to fiscal year 2013 is a result of the restructuring of the Prostiva liabilities from accounts payable and short-term deferred acquisition payment to long-term debt. |
SELECTED QUARTERLY FINANCIAL DATA
| | | | | | | | | | | | | |
| | Year Ended June 30, 2014 | |
| | First
Quarter | | Second
Quarter | | Third
Quarter | | Fourth
Quarter | |
| | (in thousands, except per share data) | |
| | | | | | | | | | | | | |
Sales | | $ | 3,779 | | $ | 3,806 | | $ | 3,356 | | $ | 3,294 | |
Gross profit | | | 1,864 | | | 1,798 | | | 849 | (1) | | 1,583 | |
Loss before income taxes | | | (1,322 | ) | | (1,069 | ) | | (1,646 | ) | | (3,587 | ) (2) |
Net Loss | | | (1,334 | ) | | (1,085 | ) | | (1,664 | ) | | (3,525 | ) (2) |
Basic net loss per share | | $ | (0.06 | ) | $ | (0.05 | ) | $ | (0.08 | ) | $ | (0.17 | ) |
Diluted net loss per share | | $ | (0.06 | ) | $ | (0.05 | ) | $ | (0.08 | ) | $ | (0.17 | ) |
| | | | | | | | | | | | | |
| | Year Ended June 30, 2013 | |
| | First
Quarter | | Second
Quarter | | Third
Quarter | | Fourth
Quarter | |
| | (in thousands, except per share data) | |
| | | | | | | | | | | | | |
Sales | | $ | 3,970 | | $ | 4,354 | | $ | 4,082 | | $ | 4,184 | |
Gross profit | | | 2,016 | | | 2,237 | | | 2,026 | | | 1,905 | (3) |
Loss before income taxes | | | (1,053 | ) | | (954 | ) | | (988 | ) | | (1,281 | ) (4) |
Net Loss | | | (1,069 | ) | | (970 | ) | | (1,005 | ) | | (1,247 | ) (4) |
Basic net loss per share | | $ | (0.05 | ) | $ | (0.05 | ) | $ | (0.05 | ) | $ | (0.06 | ) |
Diluted net loss per share | | $ | (0.05 | ) | $ | (0.05 | ) | $ | (0.05 | ) | $ | (0.06 | ) |
| (1) | Includes a $739,000 non-cash charge for the write-down of Prostiva capital equipment inventory. |
| | |
| (2) | Includes a non-cash impairment charge of $3,036,000 related to goodwill acquired as part of the Prostiva acquisition. |
| | |
| (3) | Includes a non-cash impairment charge of $274,000 related to developed technologies acquired as part of the Prostiva acquisition. |
| | |
| (4) | Includes the following non-cash charges to partially impair intangibles assets acquired as part of the Prostiva acquisition as of June 30, 2013: |
| | | | |
Developed Technologies | | $ | 274,000 | |
Customer Base | | | 95,000 | |
Trademarks | | | 65,000 | |
| | $ | 434,000 | |
32
Table of Contents
| |
ITEM 7. | MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS |
The following discussion should be read in conjunction with our financial statements and related notes contained elsewhere in this Annual Report on Form 10-K. This discussion may contain forward-looking statements based upon current expectations that involve risks and uncertainties. Our actual results and the timing of certain events could differ materially from those anticipated in these forward-looking statements as a result of risks and uncertainties, including those set forth under “Risk Factors” in Item 1A. All forward-looking statements included herein are based on information available to us as of the date hereof, and we undertake no obligation to update any such forward-looking statements.
OVERVIEW
Urologix develops, manufactures, and markets non-surgical, office-based therapies for the treatment of the symptoms and obstruction resulting from non-cancerous prostate enlargement also known as benign prostatic hyperplasia (BPH). These therapies use proprietary technology in the treatment of BPH, a disease that affects more than 30 million men worldwide and is the most common prostate problem for men over 50. We market both the Cooled ThermoTherapy™ (CTT) product line and the Prostiva® Radio Frequency (RF) Therapy System. We acquired the exclusive worldwide license to the Prostiva RF Therapy System in September 2011. These two technologies are designed to be used by urologists in their offices without placing their patients under general anesthesia. CTT uses a flexible catheter to deliver targeted microwave energy combined with a unique cooling mechanism that protects healthy urethral tissue and enhances patient comfort to provide safe, effective, lasting relief from BPH voiding symptoms by the thermal ablation of hyperplastic prostatic tissue surrounding the urethra. The proprietary Prostiva RF Therapy System delivers radio frequency energy directly into the prostate through the use of insulated electrodes deployed from a transurethral scope, ablating targeted prostatic tissue under the direct visualization of the urologist. These focal ablations reduce constriction of the urethra, thereby relieving BPH voiding symptoms. These two proven technologies have slightly different, yet complementary, patient indications and providing them to our urologist customers enables them to treat a wide range of patients in their office. We believe that these office-based BPH therapies are efficacious, safe and low cost solutions for BPH as they have shown results clinically superior to those of daily BPH medication and without the complications and side effect profile inherent with surgical procedures.
Our goal is to strengthen our business by efficiently deploying our resources to support adoption of Cooled ThermoTherapy and Prostiva RF Therapy as the preferred therapeutic options considered by urologists for their BPH patients in the earlier stages of disease progression. Typically, these are patients who do not want to take chronic BPH medication or are unhappy with the side effects, costs or results. A urologist can choose between our two therapies based upon clinical criteria specific to the BPH patient’s presentation. Our business strategy to achieve this goal is to:
| | |
| • | Increase utilization of Cooled ThermoTherapy and Prostiva RF Therapy by urologists who already have access to a Cooled ThermoTherapy and/or Prostiva RF Therapy system, |
| | |
| • | Build upon the evidence supporting the cost effectiveness of our technologies and educate healthcare providers on the benefit to patients and the healthcare system of our in-office therapies, |
| | |
| • | Educate patients and urologists on the benefits of Cooled ThermoTherapy and Prostiva RF Therapy through educational and other market development efforts, and |
| | |
| • | Continue to partner with our European distributors to support the customers outside the United States. |
Clinical research activities are focused on expanding the evidence demonstrating the cost effectiveness of our technologies. Our research and development engineering efforts and goals are currently focused primarily on continuing engineering projects to support the product lines. This includes improving the features and functions of the technologies used in our Cooled ThermoTherapy and Prostiva RF Therapy procedures; improving the ease of use, continuous quality improvement initiatives; and also reducing the manufacturing cost of our products.
33
Table of Contents
We have incurred net losses of $7.6 million in fiscal year 2014 and $4.3 million in the fiscal year ended 2013. In addition, we have accumulated aggregate net losses since the inception of business through June 30, 2014 of $126.6 million.
During the first quarter of fiscal 2012, the Company entered into a license agreement with Medtronic for the Prostiva RF Therapy System. The Company paid Medtronic $500,000 on September 6, 2011 for half of the $1,000,000 initial license fee, with the remaining $500,000 payable on September 6, 2012. On June 28, 2013, we entered into a Restructuring Agreement with Medtronic related to the $7.5 million we owed to Medtronic under the Transaction Documents. As part of this agreement, we paid Medtronic $2.0 million in satisfaction of royalties earned for the 12 months ended September 6, 2012, the second half of the initial licensing fee, the license maintenance fee for the 12 month period ended September 6, 2012, for outstanding transition services fees, and for Prostiva inventory included as part of the acquisition and purchased subsequent to the acquisition. In addition, we entered into a promissory note (the “Note”) with Medtronic for $5.3 million for the remaining amounts owed on Prostiva inventory acquired as part of the acquisition and purchased subsequent to the acquisition. Interest on the Note accrues at a rate of 6 percent, compounded annually and is payable in five equal installments of principal and accrued interest, on March 31st of each year beginning on March 31, 2015. The $206,000 difference between the $7.5 million in obligations owed to Medtronic and the $2.0 million paid and the $5.3 million Note was recorded as a gain on debt extinguishment in fiscal year 2013.
Under the license agreement, royalty payments for Prostiva products are paid one year in arrears based on the contract year. The royalty payment due during the second quarter of fiscal year 2014 of $650,000 has not been paid as of June 30, 2014 or as of the date of filing this Annual Report on Form 10-K. The $650,000 is included in the short-term deferred acquisition payment liability as of June 30, 2014. In addition, we have not paid, as of June 30, 2014 and as of the date of filing this Annual Report on Form 10-K, the annual $65,000 licensing maintenance fee due on September 6, 2013 which is included in other accrued expenses as of June 30, 2014. The non-payment does not entitle Medtronic to terminate the license agreement unless Medtronic provides written notice and an opportunity to cure the default. The non-payment under the license agreement is also not an event of default under the Note unless Medtronic provides written notice and an opportunity to cure.
During the quarter ended September 30, 2012, the Company completed a follow-on offering in which we sold 5,980,000 shares of common stock at a price of $0.75 per share which contributed approximately $3.8 million of net proceeds after deducting underwriting discounts and commissions and other expenses payable by the Company. However, as a result of the Company’s history of operating losses and negative cash flows from operations, the $2.0 million payment to Medtronic in June 3013 for liabilities associated with the Prostiva acquisition, and the remaining liabilities related to the Prostiva acquisition and Note owed to Medtronic, there is substantial doubt about our ability to continue as a going concern. In addition, our line of credit with Silicon Valley Bank expired on June 30, 2014, and was not renewed. Our cash and cash generated from operations, if any, may not be sufficient to sustain day-to-day operations for the next 12 months, particularly if product sales do not generate revenues in the amounts currently anticipated, if our operating costs are greater than anticipated or greater than our business can support, or if our cost reduction is not effective. Our ability to continue as a going concern is dependent upon improving our liquidity.
The Company is considering all available alternatives to improve its cash and liquidity position. The Company implemented restructuring plans in January 2014 and again in April 2014. The Company made the strategic decision to restructure the organization, including deploying a new distribution model and operational structure, to reduce company expenses and focus remaining resources on the most important needs of our business. These changes are designed to improve the Company’s ability to generate positive cash flow from operations. On April 10, 2014, we completed the implementation of this plan. The strategic reorganization included implementing a new sales strategy using a leaner and more efficient sales team which will continue to support our customer base in a deployment designed to create a more profitable sales model. In addition, we are piloting the use of dedicated resources charged with demonstrating our value proposition to large provider organizations such as ACOs and certain hospital systems which are highly-focused on cost-effective treatment alternatives like our in-office BPH technologies. The targeted annual savings from these restructurings total over $4 million when compared to the first half of fiscal year 2014. These savings impact both cost of goods sold and operating expenses. In the fourth quarter we received partial benefit of these changes (see Footnote 6 for further details). The Company may seek to improve its liquidity position by raising capital through additional indebtedness or an offering of its equity securities or both. However, it may be difficult to raise additional capital through a debt offering due to the debt outstanding with Medtronic and their position as a secured lender.
34
Table of Contents
Our financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that may be necessary as a result of this uncertainty.
Critical Accounting Policies and Estimates:
In accordance with Securities and Exchange Commission guidance, we set forth below those material accounting policies that we believe are the most critical to an investor’s understanding of our financial results and condition, and require complex management judgment.
Revenue Recognition
We recognize revenue from the sale of Cooled ThermoTherapy control units upon delivery to the customer, which include urologists, urology practices, mobile units, clinics and hospitals. We recognize revenue from the sale of Prostiva generators upon shipment to the customer. Revenue is recognized in accordance with generally accepted accounting principles as outlined in Accounting Standards Codification (“ASC”) 605-10-S99,Revenue Recognition, which requires that four basic criteria be met before revenue can be recognized: (i) persuasive evidence of an arrangement exists; (ii) the price is fixed or determinable; (iii) collectability is reasonably assured; and (iv) product delivery has occurred or services have been rendered. The Company recognizes revenue as products are shipped based on FOB shipping point terms when title passes to customers. In addition to our sales of Cooled ThermoTherapy control units and Prostiva generators, we place our control units and generators with customers free of charge under a variety of programs for both evaluation and long-term use, and also provide access to Cooled ThermoTherapy and Prostiva RF Therapy treatments via our Urologix mobile service. We retain title to the control units and generators placed with our customers for evaluation and longer-term use. These programs, as well as our Urologix mobile service, are designed to expand access to our technology, and thus expand the market for our single-use treatment catheters and Prostiva handpieces. The free use of our Cooled ThermoTherapy control units and Prostiva generators are bundled with the sale of single-use treatment catheters or Prostiva handpieces and scopes, respectively, and are considered a single unit of accounting. Revenue from the bundled sales is recognized when the single-use treatment catheters or handpieces and scopes are shipped to our customers. Revenue from our mobile service is recognized upon treatment of the patient. Revenue for extended warranty service contracts is deferred and recognized over the contract period on a straight-line basis. We record a provision for estimated sales returns on product sales in the same period as the related revenue is recorded. The provision for estimated sales returns is based on historical sales returns, analysis of credit memo data and specific customer-based circumstances. Should actual sales returns differ from our estimates, revisions to the sales return reserve would be required. Sales and use taxes are reported on a net basis, excluding them from revenue.
Inventories
We value our inventories, consisting primarily of control units, single-use treatment catheters, and raw materials to produce the control units and treatment catheters, at the lower of cost or market value on a first-in, first-out (“FIFO”) basis. The inventory cost includes merchandise, labor, overhead and freight. A periodic review of the inventory on hand is performed to determine if the inventory is properly stated at the lower of cost or market. In performing this analysis we consider, at a minimum, the following factors: average selling prices, reimbursement changes, and changes in demand for our products due to competitive conditions or market acceptance. Each type of inventory is analyzed to determine net realizable values. A provision is recorded to reduce the cost of inventories to the estimated net realizable values, if required (a new cost basis).
We also analyze the level of inventory on hand on a periodic basis, in relation to estimated customer requirements to determine whether write-downs for excess, obsolete, or slow-moving inventory are required. Any significant or unanticipated change in the factors noted above could have a significant impact on the value of our inventories and on our reported operating results.
35
Table of Contents
Valuation of Long-Lived Assets and Goodwill
We assess the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An asset or asset group is considered impaired if its carrying amount exceeds the undiscounted future net cash flows the asset or asset group is expected to generate. If an asset or asset group is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. If estimated fair value is less than the book value, the asset is written down to the estimated fair value and an impairment loss is recognized.
Goodwill is tested for impairment annually on April 30th or more frequently if changes in circumstance or the occurrence of events suggests an impairment may exist. To determine if there is goodwill impairment, the fair value of the reporting unit is compared to its carrying amount. If the fair value of a reporting unit is less than its carrying value, or if there is a shareholders’ deficit, an impairment loss is recorded to the extent that the fair value of the goodwill is less than the carrying value of the goodwill. The test for impairment requires us to make several estimates about fair value, most of which are based on projected future cash flows.
Considerable management judgment is necessary in estimating future cash flows and other factors affecting the valuation of long-lived assets and goodwill, including the operating and macroeconomic factors that may affect them. We use historical financial information, internal plans and projections and industry information in making such estimate.
As a result of the delisting of our common stock from the NASDAQ exchange on June 7, 2013 and the continued decline of our stock price, we tested our long-lived assets and goodwill for impairment as of June 30, 2013. Based on this impairment testing it was determined that our intangible assets acquired as part of the Prostiva acquisition were impaired. As a result, we recorded an impairment charge of $274,000 on our developed technology asset which was recorded in cost of goods sold, a $95,000 impairment charge on our customer base asset and a $65,000 impairment charge on trademarks both of which were recorded in operating expense. There was no impairment of goodwill as it was determined that the fair value of the reporting unit exceeded its carrying amount as of June 30, 2013. See Footnote 11 for a description of our intangible assets.
We tested our intangible assets and goodwill for impairment as of April 30, 2014, our annual testing date. We tested our intangible assets and goodwill for impairment due to our continued significant operating losses, negative cash flows, the estimated fair value of obligations due to Medtronic and due to the fact that we had a shareholders’ deficit as of the testing date. As part of this testing we fair valued all of our assets and liabilities as of this date using discounted cash flow analysis and forecasted future operating results. Based on this testing, we determined that the fair value of the Company could no longer support the carrying value of the goodwill acquired as part of the Prostiva acquisition. As a result, we recorded a non-cash impairment charge of $3,036,000 to fully impair our goodwill. See footnote 10 for a description of our goodwill and related impairment charge. There was no additional impairment of our long-lived assets as their estimated fair value exceeded their carrying values at that date.
Income Taxes
We utilize the asset and liability method of accounting for income taxes. We recognize deferred tax liabilities or assets for the expected future tax consequences of temporary differences between the book and tax basis of assets and liabilities. We regularly assess the likelihood that our deferred tax assets will be recovered from future taxable income. We consider projected future taxable income and ongoing tax planning strategies in assessing the amount of the valuation allowance necessary to offset our deferred tax assets that will not be recoverable. We have recorded and continue to carry a full valuation allowance against our gross deferred tax assets that will not reverse against deferred tax liabilities within the scheduled reversal period. If we determine in the future that it is more likely than not that we will realize all or a portion of our deferred tax assets, we will adjust our valuation allowance in the period we make the determination. We expect to provide a full valuation allowance on our future tax benefits until we can sustain a level of profitability that demonstrates our ability to realize these assets. As of June 30, 2014, we carried a valuation allowance of $31.5 million against our net deferred tax assets.
36
Table of Contents
Stock-Based Compensation
Stock-based compensation expense is based on the fair value of the award at the date of grant and is recognized over the requisite service period which corresponds to the vesting period. Options typically vest 25 percent after the first year of service with the remaining vesting 1/36th each month thereafter. Generally, options granted to non-employee directors are immediately exercisable at the date of grant while restricted stock awards generally vest after one year. Options are priced based on the closing price of a share of our common stock at the date of grant. The fair value of each option grant is estimated on the date of grant using the Black-Scholes option-pricing model. To determine the inputs for the Black-Scholes option pricing model, we use historical data to estimate expected volatility and the period of time that option grants are expected to be outstanding. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the estimated life of the option. The range of these assumptions and the range of option pricing and number of options granted at the different grant dates will impact our calculation of the fair value of the awards and will therefore impact the amount of expense reflected in our statement of operations for any given period. The Company also grants restricted stock awards which typically vest over a period of one to four years. Fair value for restricted stock is based on the market price on the day of grant.
Fair Value of Contingent Consideration
Contingent consideration is recorded at the acquisition date at the estimated fair value of the future royalty payments in excess of contractual minimums. The acquisition date fair value is measured based on the consideration expected to be transferred discounted back to present value. The discount rate used is determined at the time of measurement in accordance with accepted valuation methods. The fair value of the contingent consideration is remeasured to the estimated fair value at each reporting period with the change in fair value recognized as gain or loss in our statement of operations. Changes to the fair value of the contingent consideration liability occur as a result of changes in discount rates and changes in the timing and amount of projected payments.
Results of Operations
Fiscal Years Ended June 30, 2014 and 2013
Net Sales
Net sales decreased 14 percent to $14.2 million in fiscal year 2014 from $16.6 million in fiscal year 2013. The decrease in sales from fiscal year 2013 is due to a decline in the number of units sold of both our Cooled ThermoThearpy and Prostiva products.
Cost of Goods Sold and Gross Profit
Cost of goods sold includes raw materials, labor, and overhead, incurred in connection with the production of our Cooled ThermoTherapy system control units and single-use treatment catheters, amortization related to developed technologies, costs associated with the delivery of our Cooled ThermoTherapy mobile service, as well as costs for the Prostiva products. Cost of goods sold for fiscal year 2014 decreased $265,000 or 3 percent to $8.1 million, from $8.4 million in fiscal year 2013. This decrease in cost of goods sold is a result of the decrease in sales year over year, partially offset by a $739,000 non-cash charge associated with the write-down of Prostiva capital equipment inventory, as well as higher manufacturing costs due to lower production. Fiscal year 2013 costs of goods sold also included a $274,000 impairment charge related to the developed technologies acquired in the Prostiva acquisition. Excluding the $739,000 write-down of Prostiva inventory in fiscal year 2014 and the $274,000 developed technology impairment charge in fiscal year 2013, cost of goods sold would have decreased by $730,000 or 9 percent year over year.
Gross profit as a percentage of sales decreased to 43 percent from 49 percent in fiscal years 2013. The fiscal year 2014 gross margin was impacted by 5 percentage points due to the $739,000 charge associated with the write-down of Prostiva inventory noted above. Gross margin was also impacted by higher warranty expenses on the Prostiva product line and lower margins on the CTT product line due to higher manufacturing costs due to lower production. The fiscal year 2013 gross margin percentage was impacted by 2 percentage points as a result of the $274,000 developed technology impairment charge mentioned above.
37
Table of Contents
Sales and Marketing
Sales and marketing expenses in fiscal year 2014 decreased $1.9 million, or 24 percent, to $5.9 million from $7.7 million in fiscal year 2013. The decrease in sales and marketing expense is the result of a $1.0 million decrease in wages and benefits, including commissions, as a result of the restructuring activities in January and April of 2014. In addition, advertising and promotions spending decreased by $429,000, travel and entertainment decreased by $240,000 due to lower headcount, and meeting expenses decreased by $162,000.
General & Administrative
General and administrative expense in fiscal year 2014 decreased $216,000, or 9 percent, to $2.3 million from $2.5 million in fiscal year 2013. The decrease in general and administrative expense is mainly a result of a decrease in wages and benefits of $307,000 due to lower headcount, partially offset by an $81,000 increase in consulting expenses.
Research and Development
Research and development expenses, which include expenditures for product development, regulatory compliance and clinical studies, decreased to $1.6 million for fiscal year 2014, from $2.3 million in fiscal year 2013. The $644,000, or 28 percent, decrease in research and development expense is due to a $360,000 decrease in transition service fees related to the Prostiva acquisition which were paid in the prior year period. In addition, wages and benefits decreased by approximately $130,000 due to lower headcount and consulting expenses decreased by approximately $90,000.
Change in Value of Acquisition Consideration
The change in the value of acquisition consideration of $105,000 for the fiscal year ended June 30, 2014 represents the reduction in fair value of contingent consideration as a result of the reduction in projected royalty payments in excess of contractual minimums in earlier years. For the fiscal year period ended June 30, 2013, the change in value of acquisition consideration of $447,000 represents the net effect of a reduction in fair value of contingent consideration of $1.4 million prior to payments made in fiscal year 2013, partially offset by an increase of $933,000 in non-contingent consideration. These changes are due to an increase in the projected time it will take the Company to reach the cumulative $10 million of royalty and license fees owed on the Prostiva acquisition, and reduced the projected royalty payments in excess of contractual minimums in earlier years.
Impairment of Goodwill
We recorded a $3.0 million charge to fully impair our goodwill obtained in the Prostiva acquisition. As part of our annual impairment test, we fair valued all of our assets and liabilities and determined the fair value of the Company could no longer support the carrying value of goodwill on our balance sheet due to the continued operating losses of the Company along with the significant amount due Medtronic and the estimated fair value of these obligations.
Gain on Demutualization
The one-time gain on demutualization of $321,000 for the fiscal year ended June 30, 2013 represents the gain resulting from the demutualization of our products liability insurance carrier.
Medical Device Tax
The medical device excise tax represents the excise tax imposed beginning January 1, 2013 on all U.S. medical device sales as part of the Federal health care reform legislation. The increase in the medical device tax expense of $117,000 from $106,000 in fiscal year 2013 to $223,000 in fiscal year 2014 is a result of the medical device tax not being implemented until January, 2013 and therefore only represents 6 months of expenses in the prior year period versus 12 months in fiscal year 2014.
38
Table of Contents
Amortization of Identifiable Intangible Assets
Amortization of identifiable intangible assets was approximately $95,000 in fiscal year 2014 compared to $104,000 in fiscal year 2013. The slight decrease in the amortization expense is a result of the $160,000 impairment charge related to intangible assets acquired as part of the Prostiva acquisition in the fourth quarter of fiscal year 2013 which resulted in lower amortization expense over the assets remaining useful lives.
Impairment of Identifiable Intangible Assets
We recorded an impairment charge of $160,000 on identifiable intangible assets in fiscal year 2013. The impairment charge relates to a $95,000 write-down of the customer base and a $65,000 write-down of the trademarks acquired as part of the Prostiva acquisition.
Net Interest Income/(Expense)
Interest expense is the result of non-cash interest accretion on the deferred acquisition payments for the Prostiva business as well as the interest expense accrued on the Note entered into with Medtronic on June 28, 2013. Net interest expense of approximately $693,000 for the fiscal year ended June 30, 2014, increased $138,000 over interest expense of $555,000 for the fiscal year ended June 30, 2013. The increase in interest expense is due to accrued interest on the Medtronic Note signed at the end of fiscal year 2013, partially offset by lower accretion expense related to the restructuring of the license agreement with Medtronic which resulted in the re-measurement of the contingent consideration.
Gain on Debt Extinguishment
The gain on debt extinguishment of $206,000 is a result of the Restructuring Agreement entered into on June 28, 2013 with Medtronic which resulted in the restructuring of $7.5 million in outstanding Prostiva liabilities into a $2.0 million cash payment and a $5.3 million promissory note.
Provision for Income Taxes
We recorded $16,000 of income tax benefit for the fiscal year ended June 30, 2014 compared to income tax expense of $14,000 for the fiscal year ended June 30, 2013. The $16,000 income tax benefit is the result of the reversal of the deferred tax liability resulting from the impairment of goodwill created in the Prostiva acquisition in the current fiscal year, partially offset by state taxes. The income tax expense of $14,000 in fiscal year 2013 represents deferred tax expense recorded on the amortization for tax purposes of indefinite-lived goodwill as well as state taxes.
The Company utilizes the asset and liability method of accounting for income taxes. The Company recognizes deferred tax liabilities or assets for the expected future tax consequences of temporary differences between the book and tax basis of assets and liabilities. We have recorded and continue to carry a full valuation allowance against our gross deferred tax assets that will not reverse against deferred tax liabilities. We will continue to assess the assumptions used to determine the amount of our valuation allowance and may adjust the valuation allowance in future periods based on changes in assumptions of estimated future income and other factors.
Liquidity and Capital Resources
We have financed our operations since inception through sales of equity securities and, to a lesser extent, sales of our Cooled ThermoTherapy products and, beginning September 6, 2011, sales of the Prostiva RF Therapy System product. As of June 30, 2014, we had cash of $718,000 compared to cash of $2.3 million as of June 30, 2013. The decrease in cash of $1.6 million is the result of the use of $1.6 million of net cash for operating and investing activities.
39
Table of Contents
During the first quarter of fiscal 2012, the Company entered into a license agreement with Medtronic for the Prostiva RF Therapy System. The Company paid Medtronic $500,000 on September 6, 2011 for half of the $1,000,000 initial license fee, with the remaining $500,000 payable on September 6, 2012. On June 28, 2013, we entered into a Restructuring Agreement with Medtronic related to the $7.5 million we owed to Medtronic under the Transaction Documents. As part of this agreement we paid Medtronic $2.0 million in satisfaction of royalties earned for the 12 months ended September 6, 2012, the second half of the initial licensing fee, the license maintenance fee for the 12 month period ended September 6, 2012, for outstanding transition services fees, and for Prostiva inventory included as part of the acquisition and purchased subsequent to the acquisition. In addition, we entered into a promissory note (the “Note”) with Medtronic for $5.3 million for the remaining amounts owed on Prostiva inventory acquired as part of the acquisition and purchased subsequent to the acquisition. Interest on the Note accrues at a rate of 6 percent, compounded annually and is payable in five equal installments of principal and accrued interest, on March 31st of each year beginning on March 31, 2015. The $206,000 difference between the $7.5 million in obligations owed to Medtronic and the $2.0 million paid and the $5.3 million Note was recorded as a gain on debt extinguishment in fiscal year 2013. The Company does not have adequate cash to repay the full outstanding principal amount of $5.3 million on the Note. Any event of default under the Note may result in a loss of control of our business or bankruptcy.
Under the license agreement, royalty payments for Prostiva products are paid one year in arrears based on the contract year. The royalty payment due during the second quarter of fiscal year 2014 of $650,000 has not been paid as of June 30, 2014 or as of the date of filing this Annual Report on Form 10-K. The $650,000 is included in the short-term deferred acquisition payment liability as of June 30, 2014. In addition, we did not pay, as of June 30, 2014 and as of the date of filing this Annual Report on Form 10-K, the annual $65,000 licensing maintenance fee due on September 6, 2013 which is included in other accrued expenses as of June 30, 2014. The non-payment does not entitle Medtronic to terminate the license agreement unless Medtronic provides written notice and an opportunity to cure the default. The non-payment under the license agreement is also not an event of default under the Note unless Medtronic provides written notice and an opportunity to cure. In the event of a material breach of the licensing agreement or other transaction documents, and Medtronic provides written notice to the Company and the Company fails to cure the breach, Medtronic may terminate the license agreement. If the license agreement is terminated, the Company’s rights to sell the Prostiva product would be terminated.
During the first quarter of fiscal year 2013 the Company completed a follow-on offering which contributed approximately $3.8 million of net proceeds. However, as a result of the Company’s history of operating losses and negative cash flows from operations there is substantial doubt about our ability to continue as a going concern. In addition, our line of credit with Silicon Valley Bank expired on June 30, 2014, and was not renewed. It also may be difficult to raise additional capital through a debt offering due to the debt outstanding with Medtronic and their position as a secured lender. As of June 30, 2014, the Company’s cash may not be sufficient to sustain day-to-day operations for the next 12 months.
On April 10, 2014, management completed the implementation of a strategic restructuring plan which included deploying a new distribution model and operational structure to refocus the allocation of company resources and improve the Company’s ability to achieve profitability and generate positive cash flow from operations. As a result of this restructuring, cash utilization in the fourth quarter of fiscal year 2014 was $98,000, which included $80,000 of cash payments related to the restructuring for payments related to severance and accrued vacation. The targeted annual savings from this restructuring total over $4 million when compared to the first half of fiscal year 2014. However, there can be no assurance that we will be successful in improving our business or obtaining positive cash flows from operations.
The Company’s ability to continue as a going concern is dependent upon our ability to generate positive cash flows from our business and aggressively manage our expenses, including those associated with our acquisition of the Prostiva product line from Medtronic. The Company’s ability to continue as a going concern is also dependent upon avoiding an event of default under the Note and avoiding termination of the license relating to the Prostiva product, whether by negotiation with Medtronic, cure of any non-payment giving rise to an event of default or termination, or otherwise. There is no assurance that our cash and cash generated from operations, if any, will be sufficient to fund our anticipated capital needs, operating expenses (including payments under the license agreement), and Note repayments, particularly if product sales do not generate revenues in the amounts currently anticipated, if our operating costs are greater than anticipated or greater than our business can support.
40
Table of Contents
If the Company is unable to generate sufficient liquidity to meet its needs and in a timely manner, the Company may be required to further reduce expenses and curtail capital expenditures, sell assets, or suspend or discontinue operations.
There can be no assurance that the Company will be able to cure any potential event of default of the Note or cure any breach of any agreement with Medtronic, maintain compliance with its agreements with Medtronic, raise additional capital, or improve its operating or financial performance.
The fiscal year 2014 financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result should the Company be unable to continue as a going concern.
Cash Provided by Operating Activities
During fiscal year 2014, we used $1.5 million of cash from operating activities compared to $2.0 million in fiscal year 2013. The net loss of $7.6 million included non-cash charges of $3.0 million for the impairment of goodwill, $587,000 from depreciation and amortization expense, $739,000 related to the Prostiva inventory reserve, $211,000 from stock-based compensation expense and $467,000 of accreted interest expense, which was partially offset by a $105,000 gain as a result of a fair value adjustment to deferred acquisition payments. Changes in operating items resulted in the generation of $1.2 million of operating cash flow for the period as a result of lower accounts receivable of $620,000, lower inventories of $267,000, higher accounts payable of $264,000 and interest payable of $322,000. These increases were partially offset by $375,000 of lower accrued expenses and deferred income.
The decrease in accounts receivable is due to a decrease in revenue. The decrease in inventories is due to lower volumes of CTT inventory on hand due to an effort to decrease the days inventory on hand, and the increase in accounts payable is the result of the timing of receipts and services versus payment. The increase in interest payable represents the 6 percent interest accrued on the Note agreement entered into with Medtronic in June, 2013. The decrease in accrued expenses and deferred income is a result of a decrease in the commission accrual due to lower sales and lower headcount.
Cash Used for Investing Activities
We used $42,000 for investing activities related to the purchase of property and equipment to support our business operations and investments in intellectual property.
Cash Provided by Financing Activities
During fiscal year 2014 we did not generate any cash from financing activities.
Contractual Commitments
We plan to continue offering customers a variety of programs for both evaluation and longer-term use of our Cooled ThermoTherapy system control units and Prostiva RF Therapy System generators and scopes in addition to purchase options. We also will continue to provide physicians and patients with efficient access to our Cooled ThermoTherapy system control units and Prostiva RF Therapy System generators and scopes on a pre-scheduled basis through our mobile service. As of June 30, 2014, our property and equipment, net, included approximately $311,000 of control units, generators and scopes used in evaluation or longer-term use programs and units used in our Company-owned mobile service. Depending on the growth of these programs, we may use additional capital to finance these programs.
41
Table of Contents
Future contractual commitments that will affect cash flows are as follows (in thousands):
| | | | | | | | | | | | | | | | |
| | 2015 | | 2016 | | 2017 | | 2018 | | 2019 | |
Building and equipment leases | | $ | 228 | | $ | 231 | | $ | 32 | | $ | 5 | | $ | - | |
Prostiva Payments
Prostiva payments are commitments related to the acquisition of the Prostiva RF Therapy product line from Medtronic on September 6, 2011. Royalty obligations represent royalties, including minimum royalty obligations, based on management’s estimates of future revenues to be generated through sales of Prostiva products. Actual revenues generated through sales of Prostiva product and actual royalty payments may differ from these estimates. In addition, on June 28, 2013, we entered into a promissory note (the “Note”) with Medtronic for $5.3 million for the remaining amounts owed on Prostiva inventory acquired as part of the acquisition and purchased subsequent to the acquisition. Interest on the Note will accrue at a rate of 6 percent, compounded annually and is payable in five equal installments of principal and accrued interest on March 31st of each year beginning on March 31, 2015 (see Footnote 12 for more details).
| | | | | | | | | | | | | | | | |
| | Fiscal Years | |
| | 2015 | | 2016 | | 2017 | | 2018 | | 2019 | |
Prostiva Payments | | | | | | | | | | | | | | | | |
Annual license maintenance fee | | $ | 65 | | $ | 65 | | $ | 65 | | $ | 65 | | $ | 65 | |
Royalty obligations | | | 650 | | | 650 | | | 650 | | | 650 | | | 650 | |
Note payments, including interest | | | 1,323 | | | 1,323 | | | 1,323 | | | 1,323 | | | 1,323 | |
Total contractual Prostiva payments | | $ | 2,038 | | $ | 2,038 | | $ | 2,038 | | $ | 2,038 | | $ | 2,038 | |
Off Balance Sheet Arrangements
We do not have any off balance sheet arrangements.
Recently Issued Accounting Standards
Information regarding recently issued accounting pronouncements is included in Note 2 to the Financial Statements included in this Annual Report on Form 10-K.
| |
ITEM 7A. | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK |
Our financial instruments include cash and as a result we do not have a material market risk exposure.
Our policy is not to enter into derivative financial instruments. We do not have any significant foreign currency exposure since we do not generally transact business in foreign currencies. Therefore, we do not have significant overall currency exposure. In addition, we do not enter into any futures or forward commodity contracts since we do not have significant market risk exposure with respect to commodity prices.
42
Table of Contents
| |
ITEM 8. | FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA |
The following financial statements are included in the Form 10-K:
43
Table of Contents
Management’s Report on Internal Control over Financial Reporting
The Board of Directors and Shareholders
Urologix, Inc.:
Management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a15-(f) and 15d-15(f) under the Securities Exchange Act of 1934. The Company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that:
| | |
| (i) | pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; |
| | |
| (ii) | provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and |
| | |
| (iii) | provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements. |
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Under the supervision of our Chief Executive Officer/Interim Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework inInternal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on our assessment and those criteria, management concluded that the Company maintained effective internal control over financial reporting as of June 30, 2014.
* * *
This Annual Report on Form 10-K does not include an attestation report of the Company’s independent registered public accounting firm, Baker Tilly Virchow Krause, LLP regarding internal controls over financial reporting. Management’s report was not subject to attestation by Baker Tilly Virchow Krause, LLP pursuant to rules of the Securities and Exchange Commission that permit the Company to provide only management’s report in this Annual Report on Form 10-K.
44
Table of Contents
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Shareholders, Audit Committee and Board of Directors
Urologix, Inc
Minneapolis, MN
We have audited the accompanying balance sheets of Urologix, Inc. as of June 30, 2014 and 2013, and the related statements of operations, shareholders’ equity (deficit) and cash flows for the years then ended. These financial statements are the responsibility of the company’s management. Our responsibility is to express an opinion on these financial statements based on our audits.
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits included consideration of its internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management as well as evaluating the overall financial statement presentation. We believe that our audit provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Urologix, Inc. as of June 30, 2014 and 2013 and the results of their operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.
The accompanying financial statements have been prepared assuming that the company will continue as a going concern. As discussed in Note 3 to the financial statements, the company has suffered recurring operating losses and negative cash flows from operations, and needs additional working capital to support future operations. These factors raise substantial doubt about its ability to continue as a going concern. Managements’ plans in regard to these matters are also described in Note 3. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
/s/ Baker Tilly Virchow Krause, LLP
Minneapolis, Minnesota
September 19, 2014
45
Table of Contents
Urologix, Inc.
Balance Sheets
(In thousands, except per share data)
| | | | | | | |
| | June 30, | |
| | 2014 | | 2013 | |
ASSETS | | | | | | | |
Current Assets: | | | | | | | |
Cash | | $ | 718 | | $ | 2,290 | |
Accounts receivable, net of allowance of $76 and $79, respectively | | | 1,502 | | | 2,132 | |
Inventories | | | 1,397 | | | 1,571 | |
Prepaids and other current assets | | | 63 | | | 128 | |
Total current assets | | | 3,680 | | | 6,121 | |
Property and equipment: | | | | | | | |
Property and equipment | | | 12,162 | | | 12,165 | |
Less accumulated depreciation | | | (11,691 | ) | | (11,430 | ) |
Property and equipment, net | | | 471 | | | 735 | |
Other intangible assets, net | | | 1,370 | | | 1,587 | |
Goodwill | | | - | | | 3,036 | |
Long-term inventories | | | 141 | | | 1,043 | |
Other assets | | | 5 | | | 5 | |
Total assets | | $ | 5,667 | | $ | 12,527 | |
| | | | | | | |
LIABILITIES AND SHAREHOLDERS’ EQUITY/(DEFICIT) | | | | | | | |
Current liabilities: | | | | | | | |
Accounts payable | | $ | 892 | | $ | 628 | |
Accrued compensation | | | 487 | | | 721 | |
Deferred income | | | 6 | | | 5 | |
Short-term deferred acquisition payment | | | 1,339 | | | 681 | |
Current portion of long-term debt | | | 747 | | | - | |
Interest payable | | | 322 | | | - | |
Other accrued expenses | | | 499 | | | 602 | |
Total current liabilities | | | 4,292 | | | 2,637 | |
| | | | | | | |
Deferred tax liability | | | - | | | 36 | |
Long-term deferred acquisition payment | | | 3,730 | | | 4,026 | |
Long-term debt | | | 4,586 | | | 5,333 | |
Other accrued expenses | | | 36 | | | 75 | |
Total liabilities | | | 12,644 | | | 12,107 | |
Commitments and Contingencies (Note 13) | | | | | | | |
SHAREHOLDERS’ EQUITY/(DEFICIT): | | | | | | | |
Common stock, $.01 par value, 30,000 and 25,000 shares authorized; 21,291 and 20,909 shares issued; and 20,945 and 20,795 shares outstanding | | | 209 | | | 208 | |
Additional paid-in capital | | | 119,440 | | | 119,230 | |
Accumulated deficit | | | (126,626 | ) | | (119,018 | ) |
Total shareholders’ equity/(deficit) | | | (6,977 | ) | | 420 | |
Total liabilities and shareholders’ equity/(deficit) | | $ | 5,667 | | $ | 12,527 | |
The accompanying notes to financial statements are an integral part of these statements.
46
Table of Contents
Urologix, Inc.
Statements of Operations
(In thousands, except per share data)
| | | | | | | | |
| | For the Years Ended June 30 | |
| | 2014 | | | 2013 | |
SALES | | $ | 14,235 | | | $ | 16,590 | |
COST OF GOODS SOLD | | | 8,142 | | | | 8,407 | |
Gross profit | | | 6,093 | | | | 8,183 | |
| | | | | | | | |
COSTS AND EXPENSES | | | | | | | | |
Sales and marketing | | | 5,850 | | | | 7,719 | |
General and administrative | | | 2,299 | | | | 2,515 | |
Research and development | | | 1,625 | | | | 2,269 | |
Change in value of acquisition consideration | | | (105 | ) | | | (447 | ) |
Goodwill impairment | | | 3,036 | | | | - | |
Gain on demutualization | | | - | | | | (321 | ) |
Medical device tax | | | 223 | | | | 106 | |
Amortization of identifiable intangible assets | | | 95 | | | | 104 | |
Impairment of identifiable intangible assets | | | - | | | | 160 | |
Total costs and expenses | | | 13,023 | | | | 12,105 | |
OPERATING LOSS | | | (6,930 | ) | | | (3,922 | ) |
| | | | | | | | |
INTEREST INCOME/(EXPENSE) | | | (693 | ) | | | (555 | ) |
GAIN ON DEBT EXTINGUISHMENT | | | - | | | | 206 | |
FOREIGN CURRENCY EXCHANGE LOSS | | | (1 | ) | | | (7 | ) |
LOSS BEFORE INCOME TAXES | | | (7,624 | ) | | | (4,278 | ) |
INCOME TAX (BENEFIT)/EXPENSE | | | (16 | ) | | | 14 | |
NET LOSS | | $ | (7,608 | ) | | $ | (4,292 | ) |
| | | | | | | | |
NET LOSS PER COMMON SHARE - BASIC | | $ | (0.36 | ) | | $ | (0.21 | ) |
| | | | | | | | |
NET LOSS PER COMMON SHARE - DILUTED | | $ | (0.36 | ) | | $ | (0.21 | ) |
| | | | | | | | |
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC | | | 21,219 | | | | 20,703 | |
| | | | | | | | |
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - DILUTED | | | 21,219 | | | | 20,703 | |
The accompanying notes to financial statements are an integral part of these statements.
47
Table of Contents
Urologix, Inc.
Statements of Shareholders’ Equity/(Deficit)
(In thousands)
| | | | | | | | | | | | | | | | |
| | | | | | Additional
Paid-In
Capital | | Accumulated
Deficit | | Total
Shareholders’
Equity/(Deficit) | |
| | Common Stock | | | |
| | Shares | | Amount | | | |
Balance, June 30, 2012 | | | 14,719 | | $ | 147 | | $ | 115,205 | | $ | (114,726 | ) | $ | 626 | |
Net loss | | | - | | | - | | | - | | | (4,292 | ) | | (4,292 | ) |
Stock options exercised | | | 20 | | | - | | | 15 | | | - | | | 15 | |
Vesting of restricted stock | | | 76 | | | 1 | | | (1 | ) | | - | | | - | |
Stock-based compensation | | | - | | | - | | | 257 | | | - | | | 257 | |
Issuance of common stock | | | 5,980 | | | 60 | | | 3,754 | | | - | | | 3,814 | |
Balance, June 30, 2013 | | | 20,795 | | $ | 208 | | $ | 119,230 | | $ | (119,018 | ) | $ | 420 | |
Net loss | | | - | | | - | | | - | | | (7,608 | ) | | (7,608 | ) |
Vesting of restricted stock | | | 110 | | | 1 | | | (1 | ) | | - | | | - | |
Stock-based compensation | | | 40 | | | - | | | 211 | | | - | | | 211 | |
Balance, June 30, 2014 | | | 20,945 | | $ | 209 | | $ | 119,440 | | $ | (126,626 | ) | $ | (6,977 | ) |
The accompanying notes to financial statements are an integral part of these statements
48
Table of Contents
Urologix, Inc.
Statements of Cash Flows
(In thousands)
| | | | | | | |
| | For the Years Ended June 30 | |
| | 2014 | | 2013 | |
|
OPERATING ACTIVITIES | | | | | | | |
Net loss | | $ | (7,608 | ) | $ | (4,292 | ) |
Adjustments to reconcile net loss to net cash used for operating activities: | | | | | | | |
Depreciation and amortization | | | 587 | | | 674 | |
Impairment of identifiable intangible assets | | | - | | | 434 | |
Impairment of goodwill | | | 3,036 | | | - | |
Employee stock-based compensation expense | | | 211 | | | 257 | |
Provision for bad debts | | | 10 | | | (23 | ) |
Prostiva inventory reserve | | | 739 | | | - | |
Loss on disposal of assets | | | 6 | | | 7 | |
Accretion expense on deferred acquisition payments | | | 467 | | | 544 | |
Net adjustment to acquisition consideration | | | (105 | ) | | (447 | ) |
Gain on debt extinguishment | | | - | | | (206 | ) |
Deferred income taxes | | | (36 | ) | | 1 | |
Change in operating assets and liabilities: | | | | | | | |
Accounts receivable | | | 620 | | | 23 | |
Inventories | | | 267 | | | (626 | ) |
Prepaids and other assets | | | 65 | | | 162 | |
Accounts payable | | | 264 | | | 1,760 | |
Accrued expenses and deferred income | | | (375 | ) | | (227 | ) |
Interest payable | | | 322 | | | - | |
Net cash used for operating activities | | | (1,530 | ) | | (1,959 | ) |
| | | | | | | |
INVESTING ACTIVITIES | | | | | | | |
Purchases of property and equipment | | | (32 | ) | | (79 | ) |
Acquisition of business | | | - | | | (1,368 | ) |
Purchases of intellectual property | | | (10 | ) | | (32 | ) |
Net cash used for investing activities | | | (42 | ) | | (1,479 | ) |
| | | | | | | |
FINANCING ACTIVITIES | | | | | | | |
Proceeds from stock option exercises | | | - | | | 15 | |
Issuance of common stock | | | - | | | 3,814 | |
Net cash provided by financing activities | | | - | | | 3,829 | |
| | | | | | | |
NET INCREASE/(DECREASE) IN CASH | | | (1,572 | ) | | 391 | |
| | | | | | | |
CASH | | | | | | | |
Beginning of year | | | 2,290 | | | 1,899 | |
End of year | | $ | 718 | | $ | 2,290 | |
| | | | | | | |
Supplemental cash-flow information | | | | | | | |
Income taxes paid during the period | | $ | 27 | | $ | 17 | |
Net carrying amount of inventory transferred to property and equipment | | $ | 70 | | $ | 202 | |
Deferred acquisition payment and accounts payable transferred to long-term debt | | $ | - | | $ | 5,333 | |
The accompanying notes to financial statements are an integral part of these statements.
49
Table of Contents
UROLOGIX, INC.
Notes to Financial Statements
Description of Operating Activities
Urologix, Inc. (the “Company,” “Urologix,” “we”) consists of one reportable segment. Urologix is based in Minneapolis and develops, manufactures and markets minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). Urologix’ Cooled ThermoTherapy™ produces targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort. The Cooled ThermoTherapy™ product line includes the CoolWave® and Targis® Control Units and the CTC Advance® catheter. The Prostiva® RF Therapy System licensed from Medtronic, Inc., delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH voiding symptoms. Both of these products provide safe, effective and lasting relief of the symptoms and obstruction due to BPH.
| |
2. | Significant Accounting Policies |
Revenue Recognition
We recognize revenue from the sale of Cooled ThermoTherapy control units upon delivery to the customer, which include urologists, urology practices, mobile units, clinics and hospitals. We recognize revenue from the sale of Prostiva generators upon shipment to the customer. Revenue is recognized in accordance with generally accepted accounting principles as outlined in Accounting Standards Codification (“ASC”) 605-10-S99,Revenue Recognition, which requires that four basic criteria be met before revenue can be recognized: (i) persuasive evidence of an arrangement exists; (ii) the price is fixed or determinable; (iii) collectability is reasonably assured; and (iv) product delivery has occurred or services have been rendered. The Company recognizes revenue as products are shipped based on FOB shipping point terms when title passes to customers. In addition to our sales of Cooled ThermoTherapy control units and Prostiva generators, we place our control units and generators with customers free of charge under a variety of programs for both evaluation and long-term use, and also provide access to Cooled ThermoTherapy and Prostiva RF Therapy treatments via our Urologix mobile service. We retain title to the control units and generators placed with our customers for evaluation and longer-term use. These programs, as well as our Urologix mobile service, are designed to expand access to our technology, and thus expand the market for our single-use treatment catheters and Prostiva handpieces. The free use of our Cooled ThermoTherapy control units and Prostiva generators are bundled with the sale of single-use treatment catheters or Prostiva handpieces and scopes, respectively, and are considered a single unit of accounting. Revenue from the bundled sales is recognized when the single-use treatment catheters or handpieces and scopes are shipped to our customers. Revenue from our mobile service is recognized upon treatment of the patient. Revenue for extended warranty service contracts is deferred and recognized over the contract period on a straight-line basis. We record a provision for estimated sales returns on product sales in the same period as the related revenue is recorded. The provision for estimated sales returns is based on historical sales returns, analysis of credit memo data and specific customer-based circumstances. Should actual sales returns differ from our estimates, revisions to the sales return reserve would be required. Sales and use taxes are reported on a net basis, excluding them from revenue.
Allowance for Doubtful Accounts
We maintain allowances for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments. We consider factors such as past experience, credit quality of the customer base, age of the receivable balances, both individually and in the aggregate, and current economic conditions that may affect a customer’s ability to pay when determining the adequacy of the allowance. Invoices are generally due 30 days after presentation. Accounts receivable over 30 days are considered past due. Accounts receivable are written-off after management determines they are uncollectible.
50
Table of Contents
UROLOGIX, INC.
Notes to Financial Statements
Bad debt and sales returns provisions and accounts receivable write-offs for the years ended June 30, 2014 and 2013 were as follows (in thousands):
| | | | | | | | | | | | |
Years Ended | | Beginning
Balance | | Provisions | | Write-offs | | Ending
Balance |
| | | | | | | | | | | | |
June 30, 2014 | | $ | 79 | | $ | 10 | | $ | (13 | ) | $ | 76 |
| | | | | | | | | | | | |
June 30, 2013 | | | 83 | | | 38 | | | (42 | ) | | 79 |
Inventories
Inventories are stated at the lower of cost or market on a first-in, first-out (FIFO) basis and consist of:
| | | | | | | |
(in thousands) | | June 30, 2014 | | June 30, 2013 | |
| | | | | | | |
Raw materials | | $ | 685 | | $ | 734 | |
Work-in-process | | | 127 | | | 112 | |
Finished goods | | | 726 | | | 1,768 | |
Total inventories | | $ | 1,538 | | $ | 2,614 | |
We took a non-cash write-down of our Prostiva capital equipment inventory of approximately $739,000, which included approximately $504,000 of finished goods inventory acquired as part of the September 6, 2011 Prostiva acquisition in the quarter ended March 31, 2014. This inventory continues to be reserved for as of June 30, 2014. The write-down of the Prostiva capital equipment inventory was due to low volume sales of the Prostiva generators and scopes, as well as the implementations of the recent restructurings that occurred in January and April of fiscal year 2014 as a result of our change in sales strategy. In addition, as of June 30, 2014 and 2013, $141,000 and $1,043,000, respectively, of the above finished goods balance represents long-term inventories that the Company does not expect to sell within the next 12 months, however, they are not considered excess or obsolete.
Valuation of Long-Lived Assets and Goodwill
We assess the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An asset or asset group is considered impaired if its carrying amount exceeds the undiscounted future net cash flows the asset or asset group is expected to generate. If an asset or asset group is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. If estimated fair value is less than the book value, the asset is written down to the estimated fair value and an impairment loss is recognized.
Goodwill is tested for impairment annually on April 30th or more frequently if changes in circumstance or the occurrence of events suggests an impairment may exist. To determine if there is goodwill impairment, the fair value of the reporting unit is compared to its carrying amount. If the fair value of a reporting unit is less than its carrying value, or if there is a shareholders’ deficit, an impairment loss is recorded to the extent that the fair value of the goodwill is less than the carrying value of the goodwill. The test for impairment requires us to make several estimates about fair value, most of which are based on projected future cash flows.
Considerable management judgment is necessary in estimating future cash flows and other factors affecting the valuation of long-lived assets and goodwill, including the operating and macroeconomic factors that may affect them. We use historical financial information, internal plans and projections and industry information in making such estimates.
51
Table of Contents
UROLOGIX, INC.
Notes to Financial Statements
As a result of the delisting of our common stock from the NASDAQ exchange on June 7, 2013 and the continued decline of our stock price, we tested our long-lived assets and goodwill for impairment as of June 30, 2013. Based on this impairment testing it was determined that our intangible assets acquired as part of the Prostiva acquisition were impaired. As a result, we recorded an impairment charge of $274,000 on our developed technology asset which was recorded in cost of goods sold, a $95,000 impairment charge on our customer base asset and a $65,000 impairment charge on trademarks both of which were recorded in operating expense. There was no impairment of goodwill as it was determined that the estimated fair value of the reporting unit exceeded its carrying amount as of June 30, 2013. See Footnote 11 for a description of our intangible assets.
We tested our intangible assets and goodwill for impairment as of April 30, 2014, our annual testing date. We tested our intangible assets and goodwill for impairment due to our continued significant operating losses, negative cash flows, the estimated fair value of obligations due to Medtronic and due to the fact that we had a shareholders’ deficit as of the testing date. As part of this testing we fair valued all of our assets and liabilities as of this date using discounted cash flow analysis and forecasted future operating results. Based on this testing, we determined that the fair value of the Company could no longer support the carrying value of the goodwill acquired as part of the Prostiva acquisition. As a result, we recorded a non-cash impairment charge of $3,036,000 to fully impair our goodwill. See footnote 10 for a description of our goodwill and related impairment charge. There was no additional impairment of our long-lived assets as their estimated fair value exceeded their carrying values at the testing date.
Property and Equipment
Property and equipment are stated at cost. Company owned Cooled ThermoTherapy control units and Prostiva RF Therapy generators located at customer sites for evaluation and long-term use programs are transferred from inventory and classified as property and equipment that are valued at cost to manufacture and depreciated on a straight-line basis over a useful life of four years. Improvements that extend the useful lives of property and equipment are capitalized at cost and depreciated over their remaining useful lives. Repairs and maintenance are charged to expense as incurred. Depreciation is calculated using the straight-line method based upon estimated useful lives of three to seven years for machinery, equipment, furniture and vehicles. Leasehold improvements are amortized over the shorter of the useful life of the assets or term of the lease.
Property and equipment, net consisted of the following (in thousands):
| | | | | | | |
| | June 30, 2014 | | June 30, 2013 | |
| | | | | | | |
Leasehold improvements, equipment, furniture and vehicles | | $ | 147 | | $ | 241 | |
Computer equipment | | | 13 | | | 32 | |
Control units, generators and scopes | | | 311 | | | 462 | |
Total property and equipment, net | | $ | 471 | | $ | 735 | |
Depreciation expense for the years ended June 30, 2014 and 2013 was $360,000, and $401,000, respectively.
Contingent Consideration
Contingent consideration was recorded on the balance sheet at the acquisition date fair value based on the consideration expected to be transferred, discounted back to present value. The discount rate used is determined at the time of measurement in accordance with accepted valuation methods. The fair value of the contingent consideration is remeasured at the estimated fair value at each reporting period with the change in fair value recognized as income or expense in operating loss. Any changes in fair value will impact earnings in such reporting period until the contingencies are resolved.
52
Table of Contents
UROLOGIX, INC.
Notes to Financial Statements
Leases and Deferred Rent
We lease all of our office space. We evaluate and classify all of our leases as operating or capital leases for financial reporting purposes. As of June 30, 2014, all of our leases were accounted for as operating leases. For leases that contain rent escalations, we record the total rent payable during the lease term, as determined above, on a straight-line basis over the term of the lease and record the difference between the rents paid and the straight-line rent as a deferred rent. Any lease incentives we receive for items such as leasehold improvements, we record a deferred credit for the amount of the lease incentive and amortize it over the lease term, which may or may not equal the amortization period of the leasehold improvements.
Warranty Costs
Certain of our products, including the Prostiva products, are covered by warranties against defects in material and workmanship for periods of up to 24 months. We record a liability for warranty claims at the time of sale. The amount of the liability is based on the trend in the historical ratio of product failure rates, material usage and service delivery costs to sales, the historical length of time between the sale and resulting warranty claim and other factors.
Warranty provisions and claims for the years ended June 30, 2014 and 2013 were as follows (in thousands):
| | | | | | | | | | | | |
Years Ended | | Beginning
Balance | | Warranty
Provisions | | Warranty
Claims | | Ending
Balance |
| | | | | | | | | | | | |
June 30, 2014 | | $ | 58 | | $ | 36 | | $ | (38 | ) | $ | 56 |
| | | | | | | | | | | | |
June 30, 2013 | | | 47 | | | 63 | | | (52 | ) | | 58 |
Income Taxes
We utilize the asset and liability method of accounting for income taxes. We recognize deferred tax liabilities or assets for the expected future tax consequences of temporary differences between the book and tax basis of assets and liabilities. We regularly assess the likelihood that our deferred tax assets will be recovered from future taxable income. We consider projected future taxable income and ongoing tax planning strategies in assessing the amount of the valuation allowance necessary to offset our deferred tax assets that will not be recoverable. We have recorded and continue to carry a full valuation allowance against our gross deferred tax assets that will not reverse against deferred tax liabilities within the scheduled reversal period. If we determine in the future that it is more likely than not that we will realize all or a portion of our deferred tax assets, we will adjust our valuation allowance in the period we make the determination. We expect to provide a full valuation allowance on our future tax benefits until we can sustain a level of profitability that demonstrates our ability to realize these assets. As of June 30, 2014, we carried a valuation allowance of $31.5 million against our net deferred tax assets.
Stock-Based Compensation
Stock-based compensation expense is based on the fair value of the award at the date of grant and is recognized over the requisite service period which corresponds to the vesting period. Options typically vest 25 percent after the first year of service with the remaining vesting 1/36th each month thereafter. Generally, options granted to non-employee directors are immediately exercisable at the date of grant while restricted stock awards generally vest after one year. Options are priced based on the closing price of a share of our common stock at the date of grant. The fair value of each option grant is estimated on the date of grant using the Black-Scholes option-pricing model. To determine the inputs for the Black-Scholes option pricing model, we use historical data to estimate expected volatility and the period of time that option grants are expected to be outstanding. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the estimated life of the option. The range of these assumptions and the range of option pricing and number of options granted at the different grant dates will impact our calculation of the fair value of the awards and will therefore impact the amount of expense reflected in our statement of operations for any given period. The Company also grants restricted stock awards which typically vest over a period of one to four years. Fair value for restricted stock is based on the market price on the day of grant. See Note 5 for additional discussion.
53
Table of Contents
UROLOGIX, INC.
Notes to Financial Statements
Net Loss Per Common Share
Basic loss per share was computed by dividing the net loss by the weighted average number of shares of common stock and participating securities outstanding during the periods presented. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding plus all potentially dilutive common shares that result from stock options, unless there is a net loss position, in which case diluted loss per share is the same as basic loss per share. The number of shares used in earnings per share computations is as follows (in thousands):
| | | | | | | |
| | For the years ended June 30, | |
| | 2014 | | 2013 | |
Weighted average common shares outstanding - basic | | | 21,219 | | | 20,703 | |
Dilutive effect of stock options | | | - | | | - | |
Weighted average common shares outstanding - diluted | | | 21,219 | | | 20,703 | |
The dilutive effect of stock options in the above table excludes 1.7 million and 1.7 million of underlying options for which the exercise price was higher than the average market price for the years ended June 30, 2014 and 2013, respectively. In addition, there were no potentially dilutive stock options where the exercise price was lower than the average market price for the fiscal year ended June 30, 2014. For the fiscal year ended June 30, 2013, there were dilutive potential common shares of 1,061 shares, where the exercise price was lower than the average market price and were excluded from diluted weighted average common shares outstanding as they would be anti-dilutive due to our net loss.
Research and Development Costs
Research and development costs are charged to expense as incurred.
Shipping and Handling Costs
The Company includes shipping and handling revenues in sales and shipping and handling costs in cost of goods sold.
Concentration of Cash
The Company deposits its cash in what management believes are high credit quality financial institutions. The balance, at times, may exceed federally insured limits.
Financial Instruments
The carrying amounts of our accounts receivable and accounts payable approximate fair value due to their short-term nature. The fair value of the Company’s short and long-term debt, including deferred acquisition payments, is estimated based on our future projected cash flow streams which would be used to pay down the debt. As of June 30, 2014, the fair value of the Company’s short and long-term debt for purposes of the Company’s goodwill impairment analysis, including the deferred acquisition payments, was estimated at $1.9 million versus a carrying value of $10.4 million based on a market participant basis as required under the goodwill step 2 impairment test guidance. The fair value of contingent consideration as disclosed in footnote 4 and the carrying amount of debt as disclosed in footnotes 12 and 13 are based on using the contractual obligations due under the terms of the agreement.
54
Table of Contents
UROLOGIX, INC.
Notes to Financial Statements
Use of Estimates
The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. These estimates and assumptions are based on management’s best estimates and judgments. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors that management believes to be reasonable under the circumstances, including the current economic environment. The Company adjusts such estimates and assumptions when facts and circumstances dictate. These include, among others, the change in the Prostiva capital equipment inventory as noted earlier, the continued difficult economic conditions, tight credit markets, Medicare reimbursement rate uncertainty, and a decline in consumer spending and confidence, all of which have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual amounts could differ significantly from those estimated at the time the financial statements are prepared. Changes in those estimates resulting from continuing changes in the economic environment will be reflected in the financial statements in future periods.
Reclassification
The balance sheet includes the reclassification of prior year inventory from current inventories to long-term inventories to conform with current year presentation. The reclassification is related to additional inventories received subsequent to the Prostiva acquisition that should have been classified as long-term, as we do not expect to sell them within the next 12 months, which had been classified in current inventories.
Recently Issued Accounting Standard
In May 2014, the FASB issued amended revenue recognition guidance to clarify the principles for recognizing revenue from contracts with customers. The guidance requires an entity to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which an entity expects to be entitled in exchange for those goods or services. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. The requirements are effective for annual reporting periods beginning after December 15, 2016. Early adoption is not permitted. We are evaluating the impact of the amended revenue recognition guidance on our financial statements.
As of June 30, 2014, the Company had cash of $718,000. The Company incurred net losses of $7,608,000 in fiscal year 2014 and $4,292,000 in the fiscal year ended 2013. In addition, the Company has accumulated aggregate net losses from the inception of business through June 30, 2014 of $126.6 million.
During the first quarter of fiscal 2012, the Company entered into a license agreement with Medtronic for the Prostiva RF Therapy System. The Company paid Medtronic $500,000 on September 6, 2011 for half of the $1,000,000 initial license fee, with the remaining $500,000 payable on the one-year anniversary of this date, September 6, 2012. On June 28, 2013, we entered into a Restructuring Agreement with Medtronic related to the $7.5 million we owed to Medtronic under the Transaction Documents. As part of this agreement we paid Medtronic $2.0 million in satisfaction of royalties earned for the 12 months ended September 6, 2012, the second half of the initial licensing fee, the license maintenance fee for the 12 month period ended September 6, 2012, for outstanding transition services fees, and for Prostiva inventory included as part of the acquisition and purchased subsequent to the acquisition. In addition, we entered into a promissory note (the “Note”) with Medtronic for $5.3 million for the remaining amounts owed on Prostiva inventory acquired as part of the acquisition and purchased subsequent to the acquisition. Interest on the Note accrues at a rate of 6 percent, compounded annually and is payable in five equal installments of principal plus accrued interest on March 31st of each year beginning on March 31, 2015. The $206,000 difference between the $7.5 million in obligations owed to Medtronic and the $2.0 million paid and the $5.3 million Note was recorded as a gain on debt extinguishment in fiscal year 2013. The Company does not have adequate cash to repay the full outstanding principal amount of $5.3 million on the Note. Any event of default under the Note may result in a loss of control of our business or bankruptcy.
55
Table of Contents
UROLOGIX, INC.
Notes to Financial Statements
Under the license agreement, royalty payments for Prostiva products are paid one year in arrears based on the contract year. The royalty payment due during the second quarter of fiscal year 2014 of $650,000 has not been paid as of June 30, 2014 or as of the date of filing this Annual Report on Form 10-K. The $650,000 is included in the short-term deferred acquisition payment liability as of June 30, 2014. In addition, we have not paid, as of June 30, 2014 or as of the date of filing this Annual Report on Form 10-K, the annual $65,000 licensing maintenance fee due on September 6, 2013 which is included in other accrued expenses as of June 30, 2014. The non-payment does not entitle Medtronic to terminate the license agreement unless Medtronic provides written notice and an opportunity to cure the default. The non-payment under the license agreement is also not an event of default under the Note unless Medtronic provides written notice and an opportunity to cure. In the event of a material breach of the licensing agreement or other transaction documents, and Medtronic provides written notice to the Company and the Company fails to cure the breach, Medtronic may terminate the license agreement. If the license agreement is terminated, the Company’s rights to sell the Prostiva product would be terminated.
During the first quarter of fiscal 2013, the Company completed a follow-on offering in which we sold 5,980,000 shares of common stock at a price of $0.75 per share which contributed approximately $3.8 million of net proceeds after deducting underwriting discounts and commissions and other expenses payable by the Company. However, as a result of the Company’s history of operating losses and negative cash flows from operations, and the need for additional working capital to support future operations, there is substantial doubt about our ability to continue as a going concern. In addition, our line of credit with Silicon Valley Bank expired on June 30, 2014, and was not renewed.
The Company’s cash may not be sufficient to sustain day-to-day operations for the next 12 months. The Company’s ability to continue as a going concern is dependent upon our ability to generate positive cash flows from our business and aggressively manage our expenses, including those associated with our acquisition of the Prostiva product line from Medtronic. The Company’s ability to continue as a going concern is also dependent upon avoiding an event of default under the Note and avoiding termination of the license relating to the Prostiva product, whether by negotiation with Medtronic, cure of any non-payment giving rise to an event of default or termination, or otherwise.
The Company is considering all available alternatives to improve its cash and liquidity position. In particular, the Company implemented a new sales strategy using a leaner and more efficient sales team which will continue to support our current customer base while also targeting new accounts which align with our value proposition of strong clinical outcomes and low costs in an attempt to generate revenues both from sales of our Cooled ThermoTherapy and Prostiva products in an amount sufficient to improve cash flow from our business. The Company also implemented restructuring plans in January 2014 and again in April 2014 to reduce our cash utilization. The targeted annual savings from these restructurings total over $4 million, compared with the first half of fiscal year 2014. In the fourth quarter, we received partial benefit of these changes (see Footnote 6 for further details). The Company may also seek to improve its liquidity position by raising capital through additional indebtedness or an offering of its equity securities or both. However, it may be difficult to raise additional capital through a debt offering due to the debt outstanding with Medtronic and their position as a secured lender.
56
Table of Contents
UROLOGIX, INC.
Notes to Financial Statements
There is no assurance that our cash, cash generated from operations, if any, will be sufficient to fund our anticipated capital needs, operating expenses, (including payments under the licensing agreement), and Note repayments, particularly if product sales do not generate revenues in the amounts currently anticipated, if our operating costs are greater than anticipated or greater than our business can support.
If the Company is unable to generate sufficient liquidity to meet its needs and in a timely manner, the Company may be required to further reduce expenses and curtail capital expenditures, sell assets, or suspend or discontinue operations. In addition, there can be no assurance that the Company will be able to cure any potential event of default of the Note or cure any breach of any agreement with Medtronic, maintain compliance with its agreements with Medtronic, raise additional capital, or improve its operating or financial performance.
The financial statements as of and for the year ended June 30, 2014 do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result should the Company be unable to continue as a going concern.
| |
4. | Fair Value Measurements |
The Company follows the authoritative guidance on fair value measurements and disclosures with respect to assets and liabilities that are measured at fair value on both a recurring and non-recurring basis. Under this guidance, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. The hierarchy is broken down into three levels defined as follows:
| | |
| • | Level 1 - Inputs are quoted prices in active markets for identical assets or liabilities. |
| | |
| • | Level 2 - Inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly. |
| | |
| • | Level 3 - Inputs are unobservable for the asset or liability. |
As part of the consideration for the Prostiva acquisition, the estimated royalty payments between the minimum and maximum amounts are considered contingent consideration. The contingent consideration, including the payment up to the minimum obligation to transfer the license, is measured at fair value at the acquisition date and is remeasured to fair value at each reporting date until the contingency is resolved using Level 3 inputs. The Level 3 inputs consist of the projected fiscal year of payments based on projected revenues and an estimated discount rate. The fair value is determined by applying an appropriate discount rate that reflects the risk factors associated with the payment streams. The changes in fair value that do not relate to the initial recognition of the liability as of the acquisition date are recognized in earnings. The Company estimates the fair value of the future contingent consideration at $953,000 at June 30, 2014. The Company recognized a reduction in fair value of contingent consideration of $105,000 during the fiscal year ended June 30, 2014 as a result of the reduction in the projected royalty payments in excess of contractual minimums. There was no change in the fair value of non-contingent consideration. The following table provides a reconciliation of the beginning and ending balances of the contingent consideration liability:
| | | | | | | |
(in thousands) | | Fiscal Year
2013 | | Fiscal Year
2014 | |
Beginning Balance - Contingent Consideration Liability | | $ | 2,862 | | $ | 962 | |
Accretion expense | | | (11 | ) | | 96 | |
Change in fair value of contingent consideration | | | (1,380 | ) | | (105 | ) |
Payments | | | (509 | ) | | - | |
Ending Balance - Contingent Consideration Liability | | $ | 962 | | $ | 953 | |
57
Table of Contents
UROLOGIX, INC.
Notes to Financial Statements
As part of our annual testing, we tested our goodwill for impairment as of April 30, 2014. As part of this impairment testing, we fair valued all of our assets and liabilities, many of which were based on discounted cash flows analysis and forecasted future operating results which represent Level 3 inputs. As a result of our testing, we recorded a non-cash impairment charge of $3,036,000 to fully impair our goodwill. The following table provides a reconciliation of the beginning and ending balances of our goodwill intangible asset:
| | | | |
(in thousands) | | Fiscal Year
2014 | |
Beginning Balance - Goodwill | | $ | 3,036 | |
Impairment charge | | | (3,036 | ) |
Ending Balance - Goodwill | | $ | - | |
As a result of the delisting of our common stock from the NASDAQ exchange at the start of trading on June 7, 2013 and the continued decline of our stock price, we tested our long-lived assets and goodwill for impairment as of June 30, 2013. Based on this impairment testing it was determined that our intangible assets acquired as part of the Prostiva acquisition with carrying amount of $1.9 million were impaired (See Note 11). As a result, we wrote the intangible assets down to their implied fair value of $1.5 million and recorded an impairment charge of $434,000. The fair value of patents and technology, customer base and trademark intangible assets was determined based on a discounted cash flow analysis of forecasted future operating results, which represents Level 3 assets measured at fair value on a nonrecurring basis subsequent to its original recognition. The following table provides a reconciliation of the beginning and ending balances of intangible assets:
| | | | | | | |
(in thousands) | | Fiscal Year
2013 | | Fiscal Year
2014 | |
Beginning Balance - Intangible Assets | | $ | 2,177 | | $ | 1,495 | |
Amortization expense | | | (248 | ) | | (194 | ) |
Impairment charge | | | (434 | ) | | - | |
Ending Balance - Intangible Assets | | $ | 1,495 | | $ | 1,301 | |
| |
5. | Stock Options and Restricted Stock Awards |
On November 16, 2012, our shareholders approved a new equity compensation plan, the Urologix, Inc. 2012 Stock Incentive Plan (the “2012 Plan”). The 2012 Plan replaced our Amended and Restated 1991 Stock Option Plan (the “1991 Plan”) and provides stock incentive awards in the form of options (incentive and non-qualified), stock appreciation rights, restricted stock, restricted stock units, performance stock, performance units, and other awards in stock and/or cash. As of June 30, 2014, we had reserved 1,860,328 shares of common stock under the 2012 Plan, which includes 260,328 expired and forfeited shares from the 1991 Plan and 1,319,354 shares were available for future grants. The number of shares available under the 2012 Plan will be increased by an amount equal to the number of shares subject to awards or options granted under the 1991 Plan, which would have become available for additional awards under the 1991 Plan by reason of the forfeiture, cancellation, expiration or termination of those awards. Options expire 10 years from the date of grant and typically vest 25 percent after the first year of service with the remaining vesting 1/36th each month thereafter. The Company issues new shares when stock options are exercised.
58
Table of Contents
UROLOGIX, INC.
Notes to Financial Statements
Amounts recognized in the financial statements related to stock-based compensation for the fiscal years ended June 30, 2014 and 2013 were as follows (in thousands):
| | | | | | | |
| | 2014 | | 2013 | |
Cost of goods sold | | $ | 12 | | $ | 19 | |
Sales and marketing | | | 53 | | | 46 | |
General and administrative | | | 132 | | | 164 | |
Research and development | | | 14 | | | 28 | |
Total cost of stock-based compensation | | $ | 211 | | $ | 257 | |
The fair value of each option grant is estimated on the date of grant using the Black-Scholes option-pricing model. We use historical data to estimate expected volatility, the period of time that option grants are expected to be outstanding, as well as employee termination behavior. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the estimated life of the option. For restricted stock awards, the fair value is calculated as the market price on date of grant and we amortize the fair value on a straight-line basis over the requisite service period of the award. The following weighted-average assumptions were used to estimate the fair value of options granted during the fiscal years ended June 30, 2014 and 2013 using the Black-Scholes option-pricing model:
| | | | | | | |
| | 2014 | | 2013 | |
Volatility | | | 84.00% | | | 72.00% | |
Risk-free interest rate | | | 0.7% | | | 0.4% | |
Expected option life | | | 3.1 years | | | 3.4 years | |
Stock dividend yield | | | - | | | - | |
A summary of our options and option activity for the fiscal year ended June 30, 2014 is as follows:
| | | | | | | | | | | | | | | | | | | | | |
Options Outstanding | | | Options Exercisable | |
Range of Exercise Prices | | Outstanding as of
June 30, 2014 | | Weighted
Avg.
Remaining
Contractual
Life | | Weighted
Avg. Exercise
Price | | | Exercisable as of
June 30, 2014 | | Weighted
Avg. Exercise
Price | |
$ | 0.00 | | $ | 2.43 | | | 1,631,542 | | | 4.9 | | $ | 1.21 | | | | 1,331,973 | | $ | 1.34 | |
$ | 2.44 | | $ | 4.86 | | | 57,500 | | | 2.1 | | $ | 3.20 | | | | 57,500 | | $ | 3.20 | |
$ | 4.87 | | $ | 7.29 | | | 7,500 | | | 1.0 | | $ | 5.47 | | | | 7,500 | | $ | 5.47 | |
$ | 7.30 | | $ | 14.58 | | | 7,500 | | | 0.1 | | $ | 12.23 | | | | 7,500 | | $ | 12.23 | |
| | | | | | | 1,704,042 | | | 4.8 | | $ | 1.35 | | | | 1,404,473 | | $ | 1.50 | |
| | | | | | | | | | | | | | |
| | Number of
Options | | | Weighted-avg.
Exercise Price
Per Option | | Weighted-avg.
Remaining
Contractual
Term | | Aggregate
Intrinsic Value | |
Outstanding at July 1, 2013 | | | 1,711,430 | | | $ | 1.43 | | | | | $ | - | |
Options granted | | | 191,500 | | | | 0.38 | | | | | | | |
Options forfeited | | | (88,063 | ) | | | 0.66 | | | | | | | |
Options expired | | | (110,825 | ) | | | 1.49 | | | | | | | |
Outstanding at June 30, 2014 | | | 1,704,042 | | | $ | 1.35 | | | 4.79 | | $ | - | |
Exercisable at June 30, 2014 | | | 1,404,473 | | | $ | 1.50 | | | 4.02 | | $ | - | |
There is no aggregate intrinsic value in the table above as our closing stock price of $0.18 and $0.17 on June 30, 2014 and June 28, 2013, respectively, the last trading day prior to June 30, 2013, was lower than all options outstanding and exercisable as of that date.
59
Table of Contents
UROLOGIX, INC.
Notes to Financial Statements
The weighted average fair value of our options at their grant date was approximately $0.21 and $0.40 for options granted during the fiscal years ended June 30, 2014 and 2013, respectively. No options were exercised in fiscal year 2014. There was a negative intrinsic value of approximately $600 on options exercised during fiscal year 2013, as some options were exercised at a market price lower than the exercise price.
A summary of the status of our non-vested options as of June 30, 2014 is as follows:
| | | | | | | | |
| | Number of
Options | | | Weighted-avg.
Grant-Date
Fair Value | |
Non-vested at June 30, 2013 | | | 383,115 | | | $ | 0.46 | |
Options granted | | | 191,500 | | | | 0.21 | |
Options forfeited | | | (88,063 | ) | | | 0.34 | |
Options vested | | | (186,983 | ) | | | 0.48 | |
Non-vested at June 30, 2014 | | | 299,569 | | | $ | 0.32 | |
A summary of restricted stock award activity is as follows:
| | | | | | | | |
| | Number of
Restricted
Stock Awards | | | Weighted-avg.
Grant-Date
Fair Value | |
Non-vested at June 30, 2013 | | | 113,667 | | | $ | 0.68 | |
Awards granted | | | 377,500 | | | | 0.28 | |
Awards forfeited | | | (35,000 | ) | | | 0.38 | |
Awards vested | | | (109,865 | ) | | | 0.67 | |
Non-vested at June 30, 2014 | | | 346,302 | | | $ | 0.28 | |
As of June 30, 2014, total unrecognized compensation cost related to non-vested stock options and restricted stock awards granted under our plan was $86,000 and $24,000, respectively. That cost is expected to be recognized over a weighted-average period of 2.0 years for non-vested stock options and 0.36 years for restricted stock awards. The total fair value of options vested during the fiscal years ended June 30, 2014 and 2013 was $89,000 and $140,000, respectively.
On January 3, 2014, the Company implemented a restructuring plan, reorganizing the Company’s operations and sales departments. The restructuring expenses totaled approximately $41,000. On April 10, 2014, the Company implemented a second restructuring plan, making additional changes to the Company’s operations and sales departments. The restructuring included another reduction in work force and severance payments of approximately $45,000. Of the $86,000 of expenses related to the two restructurings, approximately $26,000 was included in cost of goods sold and $60,000 was included in operating expense in fiscal year 2014. A summary of the restructuring activity is as follows:
| | | | |
| | Employee
Termination
Costs | |
| | | | |
Balance as of June 30, 2013 | | $ | - | |
Restructuring charges | | | 86 | |
Payments | | | (86 | ) |
Balance as of June 30, 2014 | | $ | - | |
60
Table of Contents
UROLOGIX, INC.
Notes to Financial Statements
The Company made the strategic decision to restructure the organization, including deploying a new distribution model and operational structure to refocus the allocation of company resources and improve the Company’s ability to achieve profitability and generate positive cash flow from operations. The strategic reorganization included implementing a leaner and more efficient sales team which will continue to support our customer base in a deployment designed to create a more profitable sales model.
As a result of these restructurings cash utilization in the fourth quarter of fiscal year 2014 was $98,000, which included $80,000 of cash payments related to the April 10th restructuring for payments related to severance and accrued vacation.
Other accrued expenses is comprised of the following as of June 30 (in thousands):
| | | | | | | |
| | 2014 | | 2013 | |
Sales tax accrual | | $ | 79 | | $ | 126 | |
Other | | | 420 | | | 476 | |
Total other accrued expenses | | $ | 499 | | $ | 602 | |
The components of income tax expense (benefit) for the periods ended June 30, 2014 and 2013 consist of the following (in thousands):
| | | | | | | | | | | | | | | | | | | |
| | For the fiscal year ended June 30, | |
| | 2014 | | 2013 | |
| | Current | | Deferred | | Total | | Current | | Deferred | | Total | |
Federal | | $ | - | | $ | (33 | ) | $ | (33 | ) | $ | - | | $ | 1 | | $ | 1 | |
State | | | 20 | | | (3 | ) | | 17 | | | 13 | | | - | | | 13 | |
Total | | $ | 20 | | $ | (36 | ) | $ | (16 | ) | $ | 13 | | $ | 1 | | $ | 14 | |
A reconciliation of our statutory tax expense (benefit) to our actual tax expense (benefit) is as follows:
| | | | | | | |
| | For the years ended June 30, | |
| | 2014 | | 2013 | |
Federal statutory rate at 34 percent | | $ | (2,592 | ) | $ | (1,459 | ) |
State taxes, net of federal tax expense (benefit) and state valuation allowance | | | (231 | ) | | (128 | ) |
Nondeductible expenses | | | 34 | | | 17 | |
Stock-based compensation | | | 29 | | | 55 | |
Adjustments to net operating losses and credits | | | 918 | | | 5,562 | |
Adjustments to deferred tax assets | | | 485 | | | - | |
Other | | | 1 | | | 3 | |
Change in valuation allowance | | | 1,340 | | | (4,036 | ) |
| | $ | (16 | ) | $ | 14 | |
61
Table of Contents
UROLOGIX, INC.
Notes to Financial Statements
The components of our net deferred tax assets and liabilities are as follows (in thousands):
| | | | | | | |
| | June 30, | |
| | 2014 | | 2013 | |
Deferred Tax Assets: | | | | | | | |
Non-Current: | | | | | | | |
Net operating loss carry forward | | $ | 27,861 | | $ | 27,131 | |
Definite-lived intangibles | | | 2,851 | | | 2,414 | |
Alternative minimum tax credit | | | 3 | | | 3 | |
Federal and state general business credits | | | 886 | | | 865 | |
Non-qualified stock-based compensation | | | 153 | | | 536 | |
Property, plant and equipment | | | 80 | | | 64 | |
Current: | | | | | | | |
Accrued expenses | | | 582 | | | 318 | |
Gross deferred tax assets | | | 32,416 | | | 31,331 | |
Deferred Tax Liabilities: | | | | | | | |
Non-Current: | | | | | | | |
Amortization of indefinite-lived intangible | | | - | | | (36 | ) |
Contingent consideration on acquisition | | | (900 | ) | | (1,155 | ) |
Gross deferred tax liabilities | | | (900 | ) | | (1,191 | ) |
Net deferred tax assets before valuation allowance | | | 31,516 | | | 30,140 | |
Less: valuation allowance | | | (31,516 | ) | | (30,176 | ) |
Total net deferred tax liability | | $ | - | | $ | (36 | ) |
The valuation allowance for deferred tax assets as of June 30, 2014 and 2013 was $31,516,000 and $30,176,000, respectively. The total valuation allowance increased by $1,340,000 for the year ended June 30, 2014. The total valuation allowance decreased $4,087,000 for the year ended June 30, 2013. A significant portion of the current year increase in valuation allowance is attributable to generating NOL carryforward tax benefits. In assessing the need for a valuation allowance, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realized of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment.
Deferred tax assets relating to the tax benefits of employee stock option grants have been reduced to reflect exercises through the year ended June 30, 2014. Certain exercises resulted in tax deductions in excess of previously recorded tax benefits. The Company’s Federal NOL carryforwards of $77,534,000 referenced below as of June 30, 2014 include $541,000 of income tax deductions in excess of previously recorded tax benefits. Although these additional tax deductions are reflected in NOL carryforwards referenced below, the related tax benefit of $184,000 will not be recognized until the deductions reduce taxes payable. Accordingly, since the tax benefit does not reduce the Company’s current taxes payable in 2014, these tax benefits are not reflected in the Company’s deferred tax assets presented above. The tax benefit of these excess deductions will be reflected as a credit to additional paid-in capital when and if recognized.
62
Table of Contents
UROLOGIX, INC.
Notes to Financial Statements
As of June 30, 2014, the expiration dates and amounts of our net operating loss carryforwards and credits for federal income tax purposes are as follows (in thousands):
| | | | | | | |
Years expiring | | Net Operating
Loss | | Credits | |
June 30, 2015 | | $ | - | | $ | - | |
June 30, 2016 – June 30, 2020 | | | 21,389 | | | - | |
June 30, 2021 – June 30, 2025 | | | 19,481 | | | 115 | |
June 30, 2026 – June 30, 2034 | | | 36,664 | | | 552 | |
| | | | | | | |
| | $ | 77,534 | | $ | 667 | |
The Company completed a Section 382 analysis of the net operating loss carryforwards through February 1, 2006. Through that analysis it was determined that none of the remaining pre-February 1, 2006 net operating loss carryforwards are subject to a Section 382 limitation. Net operating losses generated since February 1, 2006 have not been analyzed for any Section 382 limitations and therefore may or may not be fully realizable in the future.
As of June 30, 2014, the Company had approximately $14,000 of unrecognized tax benefits related to state tax liabilities which would favorably impact the effective income tax rate in any future period, if recognized. During the year ended June 30, 2014, there were no significant changes to the total gross unrecognized tax benefits. It is expected that the amount of unrecognized tax benefits for positions which we have identified will not change significantly in the next twelve months.
We recognize accrued interest and penalties related to unrecognized tax benefits as a component of income tax expense. We file income tax returns in the United States (U.S.) federal jurisdiction as well as various state jurisdictions. We are subject to U.S. federal income tax examinations by tax authorities for fiscal years after 1998 due to unexpired net operating loss carryforwards originating in and subsequent to that fiscal year. Income tax examinations we may be subject to for the various state taxing authorities vary by jurisdiction.
Deferred income as of June 30, 2014 and 2013 consists of deferred warranty service income of $6,000 and $5,000, respectively. Deferred warranty service income is for prepayments made to us for warranty service contracts and is recognized over the contract period ranging from 12 to 24 months.
The Company had approximately $3,036,000 of goodwill as of June 30, 2013, related to the acquisition of the Prostiva RF Therapy System on September 6, 2011. Goodwill is tested for impairment annually on April 30th or more frequently if changes in circumstance or the occurrence of events suggests an impairment may exist. We tested our goodwill for impairment due to our continued significant operating losses, negative cash flows, the estimated fair value of obligations due to Medtronic and due to the fact that we had a shareholders’ deficit as of the testing date. As part of this testing we fair valued all of our assets and liabilities as of this date using discounted cash flow analysis and forecasted future operating results. Based on this testing it was determined that the fair value of the Company could no longer support the carrying value of the goodwill. As a result, we recorded a non-cash impairment charge of $3,036,000 to write off the full balance of goodwill as of the testing date.
63
Table of Contents
UROLOGIX, INC.
Notes to Financial Statements
Intangible assets as of June 30, 2014 and 2013 consisted of the following (in thousands):
| | | | | | | | | | | | | | | | | | | | | | | | | |
| | June 30, 2014 | | June 30, 2013 | |
| | Carrying
Value | | Accumulated
Amortization | | Impairment | | Net
Carrying
Value | | Carrying
Value | | Accumulated
Amortization | | Impairment | | Net
Carrying
Value | |
Prostiva Acquisition | | | | | | | | | | | | | | | | | | | | | | | | | |
Patents and Technology | | $ | 1,529 | | $ | (443 | ) | $ | (274 | ) | $ | 812 | | $ | 1,529 | | $ | (311 | ) | $ | (274 | ) | $ | 944 | |
Customer Base | | | 531 | | | (154 | ) | | (95 | ) | | 282 | | | 531 | | | (108 | ) | | (95 | ) | | 328 | |
Trademarks | | | 325 | | | (53 | ) | | (65 | ) | | 207 | | | 325 | | | (37 | ) | | (65 | ) | | 223 | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
EDAP Acquisition | | | | | | | | | | | | | | | | | | | | | | | | | |
Customer Base | | | 2,300 | | | (2,294 | ) | | - | | | 6 | | | 2,300 | | | (2,270 | ) | | - | | | 30 | |
Other | | | 74 | | | (11 | ) | | - | | | 63 | | | 64 | | | (2 | ) | | - | | | 62 | |
Total intangible assets | | $ | 4,759 | | | (2,955 | ) | $ | (434 | ) | $ | 1,370 | | $ | 4,749 | | | (2,728 | ) | $ | (434 | ) | $ | 1,587 | |
Amortization expense associated with intangible assets for the fiscal years ended June 30, 2014 and 2013 was $227,000 and $274,000, respectively and includes amortization expense recorded in cost of goods sold. As a result of the delisting of our common stock from the NASDAQ exchange at the start of trading on June 7, 2013 and the continued decline of our stock price, we tested our long-lived assets and goodwill for impairment as of June 30, 2013. Based on this impairment testing it was determined that our intangible assets acquired as part of the Prostiva acquisition were impaired. As a result, we recorded an impairment charge of $274,000 on our developed technology asset which was recorded in cost of goods sold, a $95,000 impairment charge on our customer base asset and a $65,000 impairment charge on trademarks both of which were recorded in operating expense. The fair value of patents and technology, customer base and trademark intangible assets was determined based on a discounted cash flow analysis of forecasted future operating results.
All intangible assets are amortized using the straight-line method over their estimated remaining useful lives. Patents and technology, customer base and trademarks related to the Prostiva acquisition are being amortized over 9 years, 9 years, and 16 years, respectively. The customer base related to the EDAP acquisition is being amortized over its remaining useful life of 0.25 years, and other intangible assets related to patent costs are amortized upon issuance over their estimated useful lives.
Future amortization expense related to the net carrying amount of intangible assets is estimated to be as follows (in thousands):
| | | | |
Fiscal Years | | | | |
2015 | | $ | 205 | |
2016 | | | 199 | |
2017 | | | 199 | |
2018 | | | 198 | |
2019 | | | 196 | |
64
Table of Contents
UROLOGIX, INC.
Notes to Financial Statements
Promissory Note
On June 28, 2013, the Company entered into a promissory note (the “Note”) with Medtronic for $5.3 million for the remaining amounts owed on Prostiva inventory acquired as part of the acquisition and purchased subsequent to the acquisition. Interest on the principal amount of the Note will accrue at the annual rate of 6%, compounded annually. The Note requires that the Company make five equal annual payments of principal and accrued interest on March 31 of each year beginning March 31, 2015. All amounts under the Note are due and payable on March 31, 2019 or earlier upon a Change of Control (as defined in the Note). The Company may prepay the Note without penalty at any time. The Note is junior to a new lender that provides certain refinancing, but is senior in all respects (including right of payment) to all other existing or future indebtedness. The Note also specifies certain customary events of default that will entitle Medtronic, after any required notice, to declare the outstanding obligations immediately due and payable. The Note contains customary representations, warranties and covenants by the Company.
Pursuant to the terms of a Security Agreement dated as of June 28, 2013 by and between Urologix and Medtronic, the Company’s obligations under the Note are secured by a security interest in all of the Company’s assets, specifically excluding intellectual property (but including accounts receivable and proceeds of intellectual property).
| |
13. | Commitments and Contingencies |
Leases
The Company leases its facility and certain equipment under non-cancelable operating leases that expire at various dates through fiscal year 2018. Rent expense related to operating leases was approximately $229,000 and $227,000 for the years ended June 30, 2014 and 2013, respectively. On September 9, 2010, the Company entered into a new lease agreement with our current landlord, covering the same square footage, for a period of seventy-two months, effective August 1, 2010. Future minimum annual lease commitments under non-cancelable operating leases with initial terms of one year or more are as follows:
| | | | | | | | | | | | | | | | |
| | 2015 | | 2016 | | 2017 | | 2018 | | 2019 | |
Building and equipment leases | | $ | 228 | | $ | 231 | | $ | 32 | | $ | 5 | | $ | - | |
Prostiva Payments
Prostiva payments are commitments related to the acquisition of the Prostiva RF Therapy product line from Medtronic on September 6, 2011. In addition, on June 28, 2013, we entered into a promissory note (the “Note”) with Medtronic for $5.3 million for the remaining amounts owed on Prostiva inventory acquired as part of the acquisition and purchased subsequent to the acquisition.
| | | | | | | | | | | | | | | | |
| | Fiscal Years | |
| | 2015 | | 2016 | | 2017 | | 2018 | | 2019 | |
Prostiva Payments | | | | | | | | | | | | | | | | |
Annual license maintenance fee | | $ | 65 | | | 65 | | | 65 | | | 65 | | | 65 | |
Royalty obligations | | | 650 | | | 650 | | | 650 | | | 650 | | | 650 | |
Note payments, including interest | | | 1,323 | | | 1,323 | | | 1,323 | | | 1,323 | | | 1,323 | |
| | $ | 2,038 | | $ | 2,038 | | $ | 2,038 | | $ | 2,038 | | $ | 2,038 | |
65
Table of Contents
UROLOGIX, INC.
Notes to Financial Statements
Contingencies
We have been and are involved in various legal proceedings and other matters that arise in the normal course of our business, including product liability claims that are inherent in the testing, production, marketing and sale of medical devices. The ultimate liabilities, if any, cannot be determined at this time. However, based upon currently available information, we believe that the ultimate resolution of these matters will not have a material effect on the financial position, liquidity or results of operations of the Company.
Major Vendor
During the fiscal year ended June 30, 2014, the Company had purchases from one vendor that accounted for approximately 70 percent of total inventory purchases. This vendor is the supplier of our Prostiva handpieces which accounted for approximately one-third of our revenue in fiscal year 2014.
The Company provides a 401(k) savings plan to which eligible employees may make pretax payroll contributions up to the allowed limit of the Internal Revenue Service. Company matching contributions are discretionary, and none have been made to date.
| |
15. | Gain on Demutualization |
Urologix’s primary product liability insurance carrier since July 1, 2006 has been Medmarc Mutual Insurance Company (“Medmarc”). On June 27, 2012, Medmarc announced that it would become part of ProAssurance Corporation (“PRA”). In order for Medmarc to be acquired by PRA, it was required to convert from a mutual insurance company to a stock insurance company through a demutualization process. Concurrently, upon demutualization, PRA would purchase the newly-issued shares of Medmarc common stock. Under the terms of the demutualization, Urologix’s calculated portion of the cash consideration to be received was approximately $321,000. The receipt of the consideration had no direct effect on the Company’s existing insurance policy or coverage. On December 4, 2012, the majority of eligible members voted to approve the demutualization of Medmarc, and in accordance with the Plan of Conversion agreement, Urologix was eligible to receive the cash consideration upon the completion of the acquisition, or January 1, 2013. Urologix received the cash consideration of $321,000 for the demutualization in January, 2013 and recognized a gain from the demutualization in fiscal year 2013.
66
Table of Contents
| |
ITEM 9. | CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE |
None.
| |
ITEM 9A. | CONTROLS AND PROCEDURES |
(a) Evaluation of Disclosure Controls and Procedures
The Company’s Chief Executive Officer and Interim Chief Financial Officer, Gregory J. Fluet, has evaluated the Company’s disclosure controls and procedures as of June 30, 2014. Based upon his review, he has concluded that these controls and procedures are effective.
The Company’s Chief Executive Officer and Interim Chief Financial Officer used the definition of “disclosure controls and procedures” as set forth in Rule 13a-15(e) under the Exchange Act in making his conclusion as to the effectiveness of such controls and procedures.
(b)Changes in Internal Controls over Financial Reporting
There have been no changes in internal control over financial reporting that occurred during the fourth quarter ended June 30, 2014 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
The Company’s internal control report is included in this report under Item 8, under the caption “Management’s Report on Internal Control over Financial Reporting.”
| |
ITEM 9B. | OTHER INFORMATION |
None.
67
Table of Contents
PARTIII
| |
ITEM 10. | DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE |
Information required under this item is contained in the following sections of the Company’s Proxy Statement for the 2014 Annual Meeting of Shareholders (the “2014 Proxy Statement”), a definitive copy of which will be filed with the Commission within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K and is incorporated herein by reference: Election of Directors, Information Regarding Executive Officers, Section 16(a) Beneficial Ownership Reporting Compliance, Corporate Governance, and Code of Ethics.
| |
ITEM 11. | EXECUTIVE COMPENSATION |
Information required under this item is contained in the following sections of the Company’s 2014 Proxy Statement and is incorporated herein by reference: Executive Compensation, Compensation of Directors, and Employment and Change in Control Arrangements.
| |
ITEM 12. | SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS |
The information required under this item with respect to Item 403 of Regulation S-K is contained in the following sections of the Company’s 2014 Proxy Statement and is incorporated herein by reference: Security Ownership of Principal Shareholders and Management. The information required under this item with respect to Item 201(d) of Regulation S-K is contained in Item 5 of this Annual Report on Form 10-K.
| |
ITEM13. | CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE |
Information required under this item is contained in the following sections of the Company’s 2014 Proxy Statement and is incorporated herein by reference: Certain Relationships and Related Persons Transactions, Policy Regarding Transactions with Related Persons, and Corporate Governance.
| |
ITEM14. | PRINCIPAL ACCOUNTANT FEES AND SERVICES |
Information required under this item is contained in the following sections of the Company’s 2014 Proxy Statement and is incorporated herein by reference: Independent Registered Public Accountants.
68
Table of Contents
PART IV
| |
ITEM 15. | EXHIBITS AND FINANCIAL STATEMENTS SCHEDULES |
| | |
(a) | Documents filed as part of this report. |
| (1) | Financial Statements. |
| | The financial statements of the Company are set forth at Item 8. “Financial Statements and Supplementary Data” of this Annual Report on Form 10-K. |
| | |
| (2) | Financial Statement Schedules for fiscal years ended June 30, 2014 and 2013. |
| | None. |
| | |
(b) | Exhibits. |
| | | | |
Exhibit Number | | Document | | Incorporated by Reference To: |
| | | | |
3.1 | | Amended and Restated Articles of Incorporation. | | Exhibit 3.1 of the Company’s Registration Statement on Form S-1 (File No. 333-03304) filed on May 28, 1996 (the “1996 Registration Statement”). |
| | | | |
3.2 | | Amended and Restated Bylaws of Urologix, Inc., as amended on December 5, 2006. | | Exhibit 3.2 of the Company’s Form 8-K dated December 5, 2006. |
| | | | |
4.1 | | Certificate of Designation, Preferences and Rights of Series A Junior Participating Preferred Stock | | Exhibit 1 of the Company’s Registration Statement on Form 8-A (File No. 000-28414) filed January 16, 1997. |
| | | | |
10.1 | | * Amended and Restated Urologix, Inc. 1991 Stock Option Plan, as amended through June 21, 2008 | | Exhibit 10.1 of the Company’s Form 10-K for the year ended June 30, 2009. |
| | | | |
10.2 | | Letter Agreement Regarding Offer of Employment between Urologix, Inc. and Gregory Fluet dated July 14, 2008. | | Exhibit 10.1 to Current Report on Form 8-K dated July 14, 2008. |
| | | | |
10.3 | | Amended and Restated Letter Agreement Regarding Change In Control Benefits between Urologix, Inc. and Certain Executive Officers dated April 23, 2012. | | Exhibit 10.1 to Current Report on Form 8-K dated April 19, 2012. |
| | | | |
10.4 | | First Amended and Restated Lease by and between Parkers Lake I Realty LLC and Urologix, Inc. dated as of August 1, 2010 | | Exhibit 10.1 to Current Report on Form 8-K dated September 9, 2010. |
| | | | |
10.5 | | Letter Agreement regarding Offer of Employment entered into effective June 3, 2011 between Urologix, Inc. and Lisa Ackermann | | Exhibit 10.1 to Current Report on Form 8-K dated June 3, 2011 |
| | | | |
10.6 | | License Agreement dated as of September 6, 2011 by and among Medtronic, Inc., Medtronic VidaMed, Inc., and Urologix, Inc. ** | | Exhibit 10.1 to Current Report on Form 8-K dated September 6, 2011 |
| | | | |
10.7 | | Transition Services and Supply Agreement dated as of September 6, 2011 by and among Medtronic, Inc. and Urologix, Inc. ** | | Exhibit 10.2 to Current Report on Form 8-K dated September 6, 2011 |
69
Table of Contents
| | | | |
Exhibit Number | | Document | | Incorporated by Reference To: |
| | | | |
10.8 | | Acquisition Option Agreement dated as of September 6, 2011 by and among Medtronic VidaMed, Inc., Medtronic, Inc., and Urologix, Inc. | | Exhibit 10.3 to Current Report on Form 8-K dated September 6, 2011 |
| | | | |
10.9 | | Asset Purchase Agreement dated as of September 6, 2011 by and among Medtronic VidaMed, Inc., Medtronic, Inc., and Urologix, Inc. | | Exhibit 10.4 to Current Report on Form 8-K dated September 6, 2011 |
| | | | |
10.10 | | Urologix, Inc. 2012 Stock Incentive Plan | | Appendix A to the Company’s Proxy Statement for the 2012 Annual Meeting of Shareholders held on November 16, 2012 |
| | | | |
10.11 | | Restructuring Agreement and Amendment to Transaction Documents dated June 28, 2013 by and among Urologix, Inc., Medtronic, Inc. and Medtronic VidaMed, Inc. | | Exhibit 10.1 to Current Report on Form 8-K dated June 28, 2013 |
| | | | |
10.12 | | Promissory Note dated June 28, 2013 by Urologix, Inc. as borrower to Medtronic, Inc. as holder in principal amount of $5,332,537.72 | | Exhibit 10.2 to Current Report on Form 8-K dated June 28, 2013 |
| | | | |
10.13 | | Security Agreement dated as of June 28, 2013 by and between Urologix, Inc. and Medtronic, Inc. | | Exhibit 10.3 to Current Report on Form 8-K dated June 28, 2013 |
| | | | |
10.14 | | First Amendment of the Transition Services and Supply Agreement effective as of March 1, 2013 by and between Urologix, Inc. and Medtronic, Inc. | | Exhibit 10.4 to Current Report on Form 8-K dated June 28, 2013 |
| | | | |
10.15 | | First Amendment of the License Agreement effective as of March 1, 2013 by and among Urologix, Inc., Medtronic, Inc. and Medtronic VidaMed, Inc. ** | | Exhibit 10.5 to Current Report on Form 8-K dated June 28, 2013 |
| | | | |
23.1 | | Consent of Baker Tilly Virchow Krause, LLP, Independent Registered Public Accounting Firm | | Attached hereto. |
| | | | |
31.1 | | Certification of Chief Executive Officer (principal executive officer) pursuant to Rules 13a-14(a) and 15d-14(a) of the Exchange Act. | | Attached hereto. |
| | | | |
31.2 | | Certification of Chief Financial Officer (principal financial officer and principal accounting officer) pursuant to Rules 13a-14(a) and 15d-14(a) of the Exchange Act. | | Attached hereto. |
| | | | |
32 | | Certification pursuant to 18 U.S.C. §1350. | | Attached hereto. |
| |
| * Indicates a management contract or compensatory plan or arrangement. |
| ** Certain portions of this exhibit have been deleted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 24b-2. Spaces corresponding to the deleted portions are represented by brackets with asterisks. |
70
Table of Contents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Dated: September 19, 2014
| | | |
| UROLOGIX, INC. |
| |
| By: | /s/ Gregory J. Fluet | |
| Gregory J. Fluet, Chief Executive Officer |
| (principal executive officer) |
Each person whose signature appears below hereby constitutes and appoints Gregory J. Fluet as his true and lawful attorney-in-fact and agent, with full power of substitution, to sign on his behalf, individually and in each capacity stated below, all amendments and post-effective amendments to this Form 10-K and to file the same, with all exhibits thereto and any other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully and to all intents and purposes as each might or could do in person, hereby ratifying and confirming each act that said attorney-in-fact and agents may lawfully do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below on behalf of the registrant by the following persons in the capacities indicated on September 19, 2014.
| | |
Signature | | Title |
| | |
/s/ Gregory J. Fluet | | Chief Executive Officer, Interim Chief Financial Officer and Director
(principal executive officer, principal financial officer and principal accounting officer) |
Gregory J. Fluet | |
| | |
/s/ Mitchell Dann | | Director |
Mitchell Dann | | |
| | |
/s/ Sidney W. Emery, Jr. | | Director |
Sidney W. Emery, Jr. | | |
| | |
/s/ Christopher R. Barys | | Director |
Christopher R. Barys | | |
| | |
/s/ Patrick D. Spangler | | Director |
Patrick Spangler | | |
71
